

Package ‘bear’

January 2, 2012

Version 2.5.3

Date 2010-06-25

Title Average bioequivalence and bioavailability data analysis tool

Author Hsin-ya Lee, Yung-jin Lee

Maintainer Yung-jin Lee <mobilePK@gmail.com>

Depends R (>= 2.10.0), reshape, nlme, sciplot, plotrix, ICSNP, gdata

Description An average bioequivalence (ABE) and bioavailability data analysis tool including sample size estimation, noncompartmental analysis (NCA), ANOVA (lm) for a standard RT/TR 2x2x2 crossover design or a parallel study. And linear mixed effect model (lme of nlme) for a 2-treatment, 2-sequence with 2 periods or more (i.e. 2x2x3/2x2x4) replicate crossover design.

License GPL (>= 2)

URL <http://pkpd.kmu.edu.tw/bear>

Repository CRAN

Date/Publication 2010-06-29 12:29:53

R topics documented:

aic	8
AICdemo	8
AICoutput	9
AIC_BANOVA	9
ARS	9
ARS.BANOVA	10
ARSdemo	10
ARSdemo.BANOVA	10
ARSoutput	11
BANOVA	11
BANOVAanalyze	12

BANOVAcsv	12
BANOVAdata	12
BANOVAmenu	12
BANOVAoutput	13
BANOVAplot	13
bye	13
demoBANOVA	13
demomenu	14
demomenu1	14
demopara	14
demosize	14
description_AIC	14
description_ARS	15
description_BANOVA	15
description_drug	15
description_drugcode	15
description_import	16
description_load	16
description_Multipldrugcode	16
description_NCA	16
description_NCAcsv	16
description_NCAinput	17
description_ParaMIX	17
description_ParaNCAcsv	17
description_ParaNCAinput	17
description_plot	18
description_Repdrugcode	18
description_RepMIX	18
description_RepNCAcsv	18
description_RepNCAinput	19
description_size	19
description_size_para	19
description_TOST1_InAUC0INF	19
description_TOST1_InAUC0t	20
description_TOST1_InCmax	20
description_TOST_InAUC0INF	21
description_TOST_InAUC0t	21
description_TOST_InCmax	22
description_TTT	22
description_TTTAIC	23
description_TTTARS	23
description_version	23
entertitle	24
entertitle.demo	24
go	24
logdata	24
Multiple1menu	25
Multipleaic	25

MultipleAICdemo	25
MultipleAICoutput	25
MultipleAIC_BANOVA	26
MultipleARS	26
MultipleARS.BANOVA	26
MultipleARSDemo	27
MultipleARSoutput	27
MultipleBANOVA	27
MultipleBANOVAanalyze	28
MultipleBANOVAcsv	28
MultipleBANOVAdata	28
MultipleBANOVAmenu	28
MultipleBANOVAoutput	29
MultipleBANOVAplot	29
Multipledata	29
MultipledemoBANOVA	29
Multipledemomenu	30
Multipledemomenu1	30
Multiplego	30
Multiplemenu	30
MultipleNCA	31
MultipleNCA.BANOVA	31
MultipleNCA.BANOVAanalyze	31
MultipleNCA.BANOVAcsv	31
MultipleNCA.BANOVAdata	32
MultipleNCA.BANOVAmenu	32
MultipleNCAanalyze	32
MultipleNCAcsv	32
MultipleNCAdata	33
MultipleNCAdemo	33
MultipleNCAdemo.BANOVA	33
MultipleNCAmenu	33
MultipleNCAoutput	34
MultipleNCAplot	34
MultipleNCAsave	34
MultipleNCAselect	34
MultipleNCAselect.BANOVA	34
MultipleNCAselectdemo	35
MultipleNCAselectdemo.BANOVA	35
MultipleNCAselectsave	35
MultipleNCAselectsave.BANOVA	35
Multipletertitle	35
Multipletertitle.demo	36
MultipleParaAIC	36
MultipleParaAIC.MIX	36
MultipleParaAICdemo	36
MultipleParaAICoutput	37
MultipleParaARS	37

Multiplestatlmenu	51
Multiplestatmenu	51
MultipleTTT	52
MultipleTTT.BANOVA	52
MultipleTTTAIC	53
MultipleTTTAIC.BANOVA	53
MultipleTTTAICdemo	54
MultipleTTTAICoutput	54
MultipleTTTARS	55
MultipleTTTARS.BANOVA	55
MultipleTTTARSdemo	56
MultipleTTTARSoutput	56
MultipleTTTdemo	57
MultipleTTToutput	57
NCA	57
NCA.BANOVA	58
NCA.BANOVAanalyze	58
NCA.BANOVAcsv	58
NCA.BANOVAdata	58
NCA.BANOVAmenu	59
NCAanalyze	59
NCAcsv	59
NCAdata	59
NCAdemo	59
NCAdemo.BANOVA	60
NCAmenu	60
NCAoutput	60
NCAplot	60
NCAsave	61
NCAselect	61
NCAselect.BANOVA	61
NCAselectdemo	61
NCAselectdemo.BANOVA	61
NCAselectsave	62
NCAselectsave.BANOVA	62
ParaAIC	62
ParaAIC.MIX	62
ParaAICdemo	63
ParaAICoutput	63
ParaARS	63
ParaARS.MIX	64
ParaARSdemo	64
ParaARSoutput	64
Paradata	65
Parademomenu	65
Parademomenu1	65
ParademoMIX	65
Paralldata	66

Paramenu	66
ParaMIX	66
ParaMIXanalyze	66
ParaMIXcsv	67
ParaMIXdata	67
ParaMIXmenu	67
ParaMIXoutput	67
ParaNCA	67
ParaNCA.MIX	68
ParaNCA.MIXanalyze	68
ParaNCA.MIXcsv	68
ParaNCA.MIXdata	68
ParaNCA.MIXmenu	69
ParaNCAanalyze	69
ParaNCAcsv	69
ParaNCAdata	69
ParaNCAdemo	69
ParaNCAdemo.MIX	70
ParaNCAoutput	70
ParaNCAplot	70
ParaNCAsave	70
ParaNCAsselect	71
ParaNCAsselect.MIX	71
ParaNCAsselectdemo	71
ParaNCAsselectdemo.MIX	71
ParaNCAsselectsave	71
ParaNCAsselectsave.MIX	72
ParaTTT	72
ParaTTT.MIX	72
ParaTTTAIC	73
ParaTTTAIC.MIX	73
ParaTTTAICdemo	74
ParaTTTAICoutput	74
ParaTTTARS	75
ParaTTTARS.MIX	75
ParaTTTARSdemo	76
ParaTTTARSoutput	76
ParaTTTdemo	77
ParaTTToutput	77
plotsingle	77
plotsingle.para	77
plotsingle.Rep	78
prdcoun	78
Repaic	78
RepAIC.MIX	78
RepAICdemo	79
RepAICoutput	79
RepARS	79

RepARS.MIX	80
RepARSDemo	80
RepARSoutput	80
RepdemoMenu	81
RepdemoMenu1	81
RepdemoMIX	81
Replicateddata	81
RepMenu	82
RepMIX	82
RepMIXanalyze	82
RepMIXcsv	82
RepMIXdata	83
RepMIXMenu	83
RepMIXoutput	83
RepNCA	83
RepNCA.MIX	84
RepNCA.MIXanalyze	84
RepNCA.MIXcsv	84
RepNCA.MIXdata	84
RepNCA.MIXMenu	85
RepNCAanalyze	85
RepNCAcsv	85
RepNCAdata	85
RepNCAdemo	85
RepNCAdemo.MIX	86
RepNCAoutput	86
RepNCAplot	86
RepNCAsave	86
RepNCAselect	87
RepNCAselect.MIX	87
RepNCAselectdemo	87
RepNCAselectdemo.MIX	87
RepNCAselectsave	87
RepNCAselectsave.MIX	88
RepTTT	88
RepTTT.MIX	88
RepTTTAIC	89
RepTTTAIC.MIX	89
RepTTTAICdemo	90
RepTTTAICoutput	90
RepTTTARS	91
RepTTTARS.MIX	91
RepTTTARSDemo	92
RepTTTARSoutput	92
RepTTTdemo	93
RepTTToutput	93
Singlego	93
sizemenu	93

statlmenu	94
statmenu	94
TotalSingledata	94
TTT	94
TTT.BANOVA	95
TTTAIC	95
TTTAIC.BANOVA	96
TTTAICdemo	96
TTTAICoutput	97
TTTARS	97
TTTARS.BANOVA	98
TTTARSdemo	98
TTTARSoutput	99
TTTdemo	99
TTTdemo.BANOVA	100
TTToutput	100
xtick	100
ytick	100

Index	101
--------------	------------

aic	<i>Akaike information criterion (AIC) method</i>
-----	--

Description

This method selects data points to estimate $\lambda(z)$ based on the minimum AIC values. It starts with the last three data points from the concentration-time profile, performing log-linear regression to calculate the slope of that tail portion of the concentration-time curve. And then the last 4 data points, the last 5 data points, on and on until it reaches the data point right after C_{max} . Thus, this method will not include the data point of (T_{max}, C_{max}) .

AICdemo	<i>Akaike information criterion (AIC) method for demo function</i>
---------	--

Description

This method selects data points to estimate $\lambda(z)$ based on the minimum AIC values. It starts with the last three data points from the concentration-time profile, performing log-linear regression to calculate the slope of that tail portion of the concentration-time curve. And then the last 4 data points, the last 5 data points, on and on until it reaches the data point right after C_{max} . Thus, this method will not include the data point of (T_{max}, C_{max}) .

AICoutput

*Output for Adjusted R squared (ARS) method***Description**

We provides several txt outputs. 1. NCA PK.txt: → Cmax, Tmax, AUC0t, AUC0inf, AUC0t/AUC0inf, ln(Cmax), ln(AUC0t), ln(AUC0inf), MRT0inf, T1/2, Vd/F, lambda z, and Cl/F → PK parameter summary (NCA outputs) 2. plots.pdf: individual linear and semilog plots, spaghetti plots, and mean conc. plots.

3. Statistical summaries.txt

AIC_BANOVA

*Akaike information criterion (AIC) method and ANOVA***Description**

This method selects data points to estimate lambda(z) based on the minimum AIC values. It starts with the last three data points from the concentration-time profile, performing log-linear regression to calculate the slope of that tail portion of the concentration-time curve. And then the last 4 data points, the last 5 data points, on and on until it reaches the data point right after Cmax. Thus, this method will not include the data point of (Tmax, Cmax).

Statistical analysis (ANOVA(lm), 90CI...): With a two-treatment, two-period, two-sequence randomized crossover design, ANOVA statistical model includes factors of the following sources: sequence, subjects nested in sequences, period and treatment. ANOVA will be applied to obtain estimates for the adjusted differences between treatment means and the standard error associated with these differences. Log-transformed BA measures will also be analyzed.

ARS

*Adjusted R squared (ARS) method***Description**

This method selects data points to estimate lambda(z) based on the maximum adjusted R squared values. It starts with the last three data points from the concentration-time course, performing log-linear regression to calculate the slope of that tail portion of the concentration-time curve. And then the last 4 data points, the last 5 data points, on and on until it excludes the data points of Cmax. Thus, this method may exclude the data point of (Tmax, Cmax). WNL v6. has the similar algorithms like this.

ARS.BANOVA

*Adjusted R squared (ARS) method and ANOVA***Description**

Adjusted R squared (ARS) method: This method selects data points to estimate $\lambda(z)$ based on the maximum adjusted R squared values. It starts with the last three data points from the concentration-time course, performing log-linear regression to calculate the slope of that tail portion of the concentration-time curve. And then the last 4 data points, the last 5 data points, on and on until it excludes the data points of C_{max} . Thus, this method may exclude the data point of (T_{max}, C_{max}) . WNL v6. has the similar algorithms like this.

Statistical analysis (ANOVA(lm), 90CI...): With a two-treatment, two-period, two-sequence randomized crossover design, ANOVA statistical model includes factors of the following sources: sequence, subjects nested in sequences, period and treatment. ANOVA will be applied to obtain estimates for the adjusted differences between treatment means and the standard error associated with these differences. Log-transformed BA measures will also be analyzed.

ARSdemo

*Adjusted R squared (ARS) method for demo function***Description**

This method selects data points to estimate $\lambda(z)$ based on the maximum adjusted R squared values. It starts with the last three data points from the concentration-time course, performing log-linear regression to calculate the slope of that tail portion of the concentration-time curve. And then the last 4 data points, the last 5 data points, on and on until it excludes the data points of C_{max} . Thus, this method may exclude the data point of (T_{max}, C_{max}) . WNL v6. has the similar algorithms like this.

ARSdemo.BANOVA

*Adjusted R squared (ARS) method and ANOVA for demo function***Description**

Adjusted R squared (ARS) method: This method selects data points to estimate $\lambda(z)$ based on the maximum adjusted R squared values. It starts with the last three data points from the concentration-time course, performing log-linear regression to calculate the slope of that tail portion of the concentration-time curve. And then the last 4 data points, the last 5 data points, on and on until it excludes the data points of C_{max} . Thus, this method may exclude the data point of (T_{max}, C_{max}) . WNL v6. has the similar algorithms like this.

Statistical analysis (ANOVA(lm), 90CI...): With a two-treatment, two-period, two-sequence randomized crossover design, ANOVA statistical model includes factors of the following sources: sequence, subjects nested in sequences, period and treatment. ANOVA will be applied to obtain estimates for the adjusted differences between treatment means and the standard error associated with these differences. Log-transformed BA measures will also be analyzed.

ARSoutput

Output for Adjusted R squared (ARS) method

Description

We provides several txt outputs. 1. NCA PK.txt: -> Cmax, Tmax, AUC0t, AUC0inf, AUC0t/AUC0inf, ln(Cmax), ln(AUC0t), ln(AUC0inf), MRT0inf, T1/2, Vd/F, lambda z, and Cl/F -> PK parameter summary (NCA outputs) 2. plots.pdf: individual linear and semilog plots, spaghetti plots, and mean conc. plots.

3. Statistical summaries.txt

From: NCAoutput

BANOVA

Statistical analysis (ANOVA(lm), 90CI...)

Description

With a two-treatment, two-period, two-sequence randomized crossover design, ANOVA statistical model includes factors of the following sources: sequence, subjects nested in sequences, period and treatment. ANOVA will be applied to obtain estimates for the adjusted differences between treatment means and the standard error associated with these differences. Log-transformed BA measures will also be analyzed.

We investigate the assessment of equivalence in intra-subject variabilities of bioavailability between formulations. Point and interval estimates for the inter-subject and intra-subject variabilities are also provided.

Moreover, a normal distribution test procedure based on Spearman's rank and Pearson's correlation coefficient and Pitman-Morgan's adjusted F test are provided.

Finally, several tests for assumptions using the inter-subject and intra-subject residuals are discussed. Statistical tests for detection of outlying subjects such as Hotelling T2 are presented.

References

1. Chow SC and Liu JP. Design and analysis of bioavailability- bioequivalence studies. Chapman & Hall/CRC, New York (2009).
2. Liu JP and Weng CS. Detection of outlying data in bioavailability- bioequivalence studies. Statist. Med. 10, 1375-1389 (1991).

BANOVAanalyze	<i>ANOVA function</i>
---------------	-----------------------

Description

Data for ANOVA

References

Guidance for Industry. Statistical approaches to establishing Bioequivalence.

BANOVAcsv	<i>choose separator and decimal type</i>
-----------	--

Description

Separator : comma, semicolon ,white space. Decimal: comma, point.

BANOVAdata	<i>Input/Edit data for ANOVA function</i>
------------	---

Description

->subject no.(subj) ->drug 1:Reference 2:Test ->sequence (seq) Sequence 1:Reference->Test sequence Sequence 2:Test->Reference sequence ->period (prd) Period 1: first treatment period Period 2: second treatment period ->Cmax ->AUC0t: area under the predicted plasma concentration time curve for test data. (time = 0 to t) ->AUC0INF: area under the predicted plasma concentration time curve for test data. (time = 0 to infinity) ->LnCmax: Log-transformed Cmax ->LnAUC0t: Log-transformed AUC0t ->LnAUC0INF: Log-transformed AUC0INF

BANOVAmenu	<i>List of ANOVA Menu</i>
------------	---------------------------

Description

You can use the functions as follows: 1.Statistical analysis (ANOVA(lm), 90CI...) 2.Demo for Statistical analysis (ANOVA(lm), 90CI...)

BANOVAoutput

*Output of ANOVA function***Description**

We provides several txt outputs. 1.ANOVA stat.txt →ANOVA:Cmax, AUC0t, AUC0inf, ln(Cmax), ln(AUC0t), ln(AUC0inf) →90CI: ln(Cmax), ln(AUC0t), and ln(AUC0inf)

BANOVApplot

*BANOVApplot***Description**

We provides several pdf. outputs about BANOVA plots for outlier detections. 1.Normal Probability Plot of lnCmax (intrasubj) 2.Normal Probability Plot of lnCmax (intersubj) 3.lnCmax(expected value) vs. studentized residuals(intrasubj) 4.lnCmax(expected value) vs. studentized residuals(intersubj) 5.Normal Probability Plot of lnAUC0t (intrasubj) 6.Normal Probability Plot of lnAUC0t (intersubj) 7.lnAUC0t(expected value) vs. studentized residuals(intrasubj) 8.lnAUC0t(expected value) vs. studentized residuals(intersubj) 9.Normal Probability Plot of lnAUC0INF (intrasubj) 10.Normal Probability Plot of lnAUC0INF (intersubj) 11.lnAUC0INF(expected value) vs. studentized residuals(intrasubj) 12.lnAUC0INF(expected value) vs. studentized residuals(intersubj)

bye

*The final step Menu***Description**

try again or leave bear package.

demoBANOVA

*Statistical analysis (ANOVA(lm), 90CI...)for demo file***Description**

With a two-treatment, two-period, two-sequence randomized crossover design, ANOVA statistical model includes factors of the following sources: sequence, subjects nested in sequences, period and treatment. ANOVA will be applied to obtain estimates for the adjusted differences between treatment means and the standard error associated with these differences. Log-transformed BA measures will also be analyzed.

demomenu *menu for NCA demo file*

Description

lambda z est. from the exact 3 data points, lambda z est. with adjusted R sq. (ARS), lambda z est. with Akaike information criterion (AIC), lambda z est. with Two-Times-Tmax method (TTT), lambda z est. with TTT and ARS, lambda z est. with TTT and AIC

demomenu1 *menu for NCA demo file*

Description

lambda z est. from the exact 3 data points→ Statistical analysis, lambda z est. with adjusted R sq. (ARS)→ Statistical analysis, lambda z est. with Akaike information criterion (AIC)→ Statistical analysis, lambda z est. with Two-Times-Tmax method (TTT)→ Statistical analysis, lambda z est. with TTT and ARS→ Statistical analysis, lambda z est. with TTT and AIC→ Statistical analysis,

demopara *Demo for sample size estimation*

Description

Demo file for sample size estimation (crossover and replicated study)function

demosize *Demo for sample size estimation*

Description

Demo file for sample size estimation (crossover and replicated study)function

description_AIC *Description for Akaike information criterion (AIC) method*

Description

This method selects data points to estimate lambda(z) based on the minimum AIC values. It starts with the last three data points from the concentration-time profile, performing log-linear regression to calculate the slope of that tail portion of the concentration-time curve. And then the last 4 data points, the last 5 data points, on and on until it reaches the data point right after C_{max}. Thus, this method will not include the data point of (T_{max}, C_{max}).

description_ARS *Description for Adjusted R squared (ARS) method*

Description

This method selects data points to estimate lambda(z) based on the maximum adjusted R squared values. It starts with the last three data points from the concentration-time course, performing log-linear regression to calculate the slope of that tail portion of the concentration-time curve. And then the last 4 data points, the last 5 data points, on and on until it excludes the data points of Cmax. Thus, this method may exclude the data point of (Tmax, Cmax). WNL v6. has the similar algorithms like this.

description_BANOVA *Description for ANOVA*

Description

Statistical analysis (ANOVA(lm), 90CI...): With a two-treatment, two-period, two-sequence randomized crossover design, ANOVA statistical model includes factors of the following sources: sequence, subjects nested in sequences, period and treatment. ANOVA will be applied to obtain estimates for the adjusted differences between treatment means and the standard error associated with these differences. Log-transformed BA measures will also be analyzed.

description_drug *Description for drug*

Description

drug 1: Ref. drug 2: Test

description_drugcode *Description for drug code*

Description

Data Codes: Drug: 1: Ref. 2: Test Sequence: 1: Ref. -> Test 2: Test -> Ref. Period: 1: 1st-treatment period 2: 2nd-treatment period

description_import *Description for import csv*

Description

Description for import csv file

description_load *Description for load Rdata*

Description

Description for load Rdata file

description_Multipldrugcode
Description for drug code for multiple study

Description

Data Codes: Drug: 1: Ref. 2: Test Sequence: 1: Ref. -> Test 2: Test -> Ref. Period: 1: 1st-treatment period 2: 2nd-treatment period

description_NCA *Description for Noncompartmental analysis (NCA)*

Description

Noncompartmental analysis (NCA) approach is used to compute AUCs and the terminal elimination rate constants (λz) for drug plasma concentration. The linear trapezoidal method is applied to calculate AUC(time 0 to the last measurable Cp). The extrapolated AUC (from time of the last measurable Cp to time infinity) is equal to the last measurable Cp divided by λz .

description_NCAcsv *Description for NCA csv file*

Description

Data file should consist of row1: column title, such as subj, seq, prd, time, conc & etc. column1: subject no.(subj) column2: sequence (seq) -> Sequence = 1 if Ref.->Test -> Sequence = 2 if Test->Ref. column3: period (prd) -> Period = 1: the 1st-treatment period -> Period = 2: the 2nd-treatment period column4: sampling time column5: drug plasma/serum/blood concentration (conc)

description_NCAinput *Description for NCA input data*

Description

Input/Edit Data -> subject no.(subj) -> sequence (seq) 1:Ref.->Test 2:Test->Ref. -> period (prd)
1: 1st-treatment period 2: 2nd-treatment period -> sampling time -> drug plasma/serum/blood
concentration (conc)

description_ParamIX *Description for lme for parallel study*

Description

With a two-treatment, two-sequence, one-period, parallel design, bear deploys the linear mixed effect model (lme). The statistical model includes a factor regarding only one source of variation - treatment. There are no sources of variation associated with sequence or period because there are no sequences or periods in a parallel design. Moreover, lme in nlme package is used to obtain estimates for the adjusted differences between treatment means and the standard error. Log-transformed BA measures will also be analyzed.

description_ParaNCAcsv
Description for NCA csv file for parallel study

Description

Data file should consist of row1: column title, such as subj, drug, time, conc & etc. column1: subject no.(subj) column2: treatment (drug) column3: sampling time column4: drug plasma/serum/blood concentration (conc)

description_ParaNCAinput
Description for NCA input data for parallel study

Description

Input/Edit Data -> subject no.(subj) -> treatment (drug) 1: Ref. 2: Test -> sampling time -> drug plasma/serum/blood concentration (conc)

description_plot *Description for plot*

Description

Authors: Hsin-ya Lee, Yung-jin Lee 100, Shih-chuan 1st Rd. College of Pharmacy, Kaohsiung Medical University, Kaoshiung, Taiwan 80708 E-mail: hsinyalee@gmail.com, pkpd.taiwan@gmail.com
 bear's website: <http://pkpd.kmu.edu.tw/bear> R website: www.r-project.org

description_Repdrugcode
 Description of drug code for replicated study

Description

Data Codes: Drug: 1: Ref. 2: Test

description_RepMIX *Description for lme for replicated study*

Description

With a two-treatment, more than two period, two-sequence randomized crossover design, linear mixed-effects model may be used. The lme in nlme package is used to obtain estimates for the adjusted differences between treatment means and the standard error associated with these differences. Log-transformed BA measures will also be analyzed.

description_RepNCAcsv *Description of NCA csv file for replicated study*

Description

Data file should consist of row1: column title, such as subj, seq, prd, time, conc & etc. column1: subject no.(subj) column2: sequence (seq) -> Sequence = 1 if Ref.->Test -> Sequence = 2 if Test->Ref. column3: period (prd) -> Period = 1: the 1st-treatment period -> Period = 2: the 2nd-treatment period

column4: treatment (drug) column5: sampling time column6: drug plasma/serum/blood concentration (conc)

 description_RepNCAinput

Description for NCA input data for replicated study

Description

Input/Edit Data -> subject no.(subj) -> sequence (seq) ex. 4 periods 1:Ref.->Test->Ref.->Test 2:Test->Ref.->Test->Ref. or ex. 3 periods 1:Ref.->Test->Test 2:Test->Ref.->Ref. -> period (prd) 1: 1st-treatment period 2: 2nd-treatment period 3: 3rd-treatment period 4: 4th-treatment period -> treatment (drug) 1: Ref. 2: Test -> sampling time -> drug plasma/serum/blood concentration (conc)

 description_size

Description for sample size input for crossover and replicated study

Description

Required data 1. Theta is the ratio in average BA between the two formulations expressed in percentage of the average reference BA. 2. $\Theta = U_t/U_r$, where U_t and U_r denote the median BA for the Test and the Reference products. 3. CV stands for the intra-subject coefficient of variation.

 description_size_para *Description for sample size input for parallel study*

Description

Required data 1. Theta is the ratio in average BA between the two formulations expressed in percentage of the average reference BA. 2. $\Theta = U_t/U_r$, where U_t and U_r denote the median BA for the Test and the Reference products. 3. CV stands for the inter-subject coefficient of variation.

 description_TOST1_lnAUC0INF

Description for Two One-Sided Test for lnAUC0INF

Description

Interpretation: H_0 : $MEAN_{test}/MEAN_{ref} \leq \ln(\text{lower acceptance})$ or $MEAN_{test}/MEAN_{ref} \geq \ln(\text{Upper acceptance})$ H_a : $\ln(\text{lower acceptance}) < MEAN_{test}/MEAN_{ref} < \ln(\text{Upper acceptance})$
Because all P values are less than 0.05, we will reject the null hypothesis (H_0).

References

1. Chow SC and Liu JP. Design and Analysis of Bioavailability- Bioequivalence Studies. 3rd ed., Chapman & Hall/CRC, New York (2009).
2. Schuirmann DJ. On hypothesis testing to determine if the mean of a normal distribution is contained in a known interval. *Biometrics*, 37, 617(1981).
3. Schuirmann DJ. A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. *Journal of Pharmacokinetics and Biopharmaceutics*, 15, 657-680 (1987).
4. Anderson S and Hauck WW. A new procedure for testing equivalence in comparative bioavailability and other clinical trials. *Communications in Statistics-Theory and Methods*, 12, 2663-2692 (1983).

description_TOST1_InAUC0t

Description for Two One-Sided Test for lnAUC0t

Description

Interpretation: Ho: MEAN-test/MEAN-ref \leq ln(lower acceptance) or MEAN-test/MEAN-ref \geq ln(Upper acceptance) Ha: ln(lower acceptance) < MEAN-test/MEAN-ref < ln(Upper acceptance)
Because all P values are less than 0.05, we will reject the null hypothesis (Ho).

References

1. Chow SC and Liu JP. Design and Analysis of Bioavailability- Bioequivalence Studies. 3rd ed., Chapman & Hall/CRC, New York (2009).
2. Schuirmann DJ. On hypothesis testing to determine if the mean of a normal distribution is contained in a known interval. *Biometrics*, 37, 617(1981).
3. Schuirmann DJ. A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. *Journal of Pharmacokinetics and Biopharmaceutics*, 15, 657-680 (1987).
4. Anderson S and Hauck WW. A new procedure for testing equivalence in comparative bioavailability and other clinical trials. *Communications in Statistics-Theory and Methods*, 12, 2663-2692 (1983).

description_TOST1_InCmax

Description for Two One-Sided Test for lnCmax

Description

Interpretation: Ho: MEAN-test/MEAN-ref \leq ln(lower acceptance) or MEAN-test/MEAN-ref \geq ln(Upper acceptance) Ha: ln(lower acceptance) < MEAN-test/MEAN-ref < ln(Upper acceptance)
Because all P values are less than 0.05, we will reject the null hypothesis (Ho).

References

1. Chow SC and Liu JP. Design and Analysis of Bioavailability- Bioequivalence Studies. 3rd ed., Chapman & Hall/CRC, New York (2009).
2. Schuirmann DJ. On hypothesis testing to determine if the mean of a normal distribution is contained in a known interval. *Biometrics*, 37, 617(1981).
3. Schuirmann DJ. A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. *Journal of Pharmacokinetics and Biopharmaceutics*, 15, 657-680 (1987).
4. Anderson S and Hauck WW. A new procedure for testing equivalence in comparative bioavailability and other clinical trials. *Communications in Statistics-Theory and Methods*, 12, 2663-2692 (1983).

description_TOST_InAUC0INF

Description for Two One-Sided Test for lnAUC0INF

Description

Interpretation: $H_0: \text{MEAN-test/MEAN-ref} \leq \ln(\text{lower acceptance})$ or $\text{MEAN-test/MEAN-ref} \geq \ln(\text{Upper acceptance})$
 $H_a: \ln(\text{lower acceptance}) < \text{MEAN-test/MEAN-ref} < \ln(\text{Upper acceptance})$
 If at least one of P value is more than 0.05, we will not reject the null hypothesis (H_0).

References

1. Chow SC and Liu JP. Design and Analysis of Bioavailability- Bioequivalence Studies. 3rd ed., Chapman & Hall/CRC, New York (2009).
2. Schuirmann DJ. On hypothesis testing to determine if the mean of a normal distribution is contained in a known interval. *Biometrics*, 37, 617(1981).
3. Schuirmann DJ. A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. *Journal of Pharmacokinetics and Biopharmaceutics*, 15, 657-680 (1987).
4. Anderson S and Hauck WW. A new procedure for testing equivalence in comparative bioavailability and other clinical trials. *Communications in Statistics-Theory and Methods*, 12, 2663-2692 (1983).

description_TOST_InAUC0t

Description for Two One-Sided Test for lnAUC0t

Description

Interpretation: $H_0: \text{MEAN-test/MEAN-ref} \leq \ln(\text{lower acceptance})$ or $\text{MEAN-test/MEAN-ref} \geq \ln(\text{Upper acceptance})$
 $H_a: \ln(\text{lower acceptance}) < \text{MEAN-test/MEAN-ref} < \ln(\text{Upper acceptance})$
 If at least one of P value is more than 0.05, we will not reject the null hypothesis (H_0).

References

1. Chow SC and Liu JP. Design and Analysis of Bioavailability- Bioequivalence Studies. 3rd ed., Chapman & Hall/CRC, New York (2009).
2. Schuirmann DJ. On hypothesis testing to determine if the mean of a normal distribution is contained in a known interval. *Biometrics*, 37, 617(1981).
3. Schuirmann DJ. A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. *Journal of Pharmacokinetics and Biopharmaceutics*, 15, 657-680 (1987).
4. Anderson S and Hauck WW. A new procedure for testing equivalence in comparative bioavailability and other clinical trials. *Communications in Statistics-Theory and Methods*, 12, 2663-2692 (1983).

description_TOST_InCmax

Description for Two One-Sided Test for InCmax

Description

Interpretation: H_0 : $MEAN\text{-}test/MEAN\text{-}ref \leq \ln(\text{lower acceptance})$ or $MEAN\text{-}test/MEAN\text{-}ref \geq \ln(\text{Upper acceptance})$
 H_a : $\ln(\text{lower acceptance}) < MEAN\text{-}test/MEAN\text{-}ref < \ln(\text{Upper acceptance})$
 If at least one of P value is more than 0.05, we will not reject the null hypothesis (H_0).

References

1. Chow SC and Liu JP. Design and Analysis of Bioavailability- Bioequivalence Studies. 3rd ed., Chapman & Hall/CRC, New York (2009).
2. Schuirmann DJ. On hypothesis testing to determine if the mean of a normal distribution is contained in a known interval. *Biometrics*, 37, 617(1981).
3. Schuirmann DJ. A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. *Journal of Pharmacokinetics and Biopharmaceutics*, 15, 657-680 (1987).
4. Anderson S and Hauck WW. A new procedure for testing equivalence in comparative bioavailability and other clinical trials. *Communications in Statistics-Theory and Methods*, 12, 2663-2692 (1983).

description_TTT

Description for Two Times Tmax (TTT) method

Description

The TTT method is based on the Bateman function. The Bateman function has two outstanding points. First, the maximum of the curve (C_{max} at T_{max}) and secondly, the inflection point of the curve (C_{inpt} at T_{inpt}). The inflection point of the curve describes the point where the algebraic sign of the curvature changes. T_{inpt} is equal to two times T_{max} . Thus, The twofold of the observed T_{max} value can be used as a threshold of time points to be included in the calculation of $\lambda(z)$.

description_TTTAIC *Description for Two-Times-Tmax (TTT) and Akaike information criterion (AIC)*

Description

The TTT method is based on the Bateman function. The Bateman function has two outstanding points. First, the maximum of the curve (C_{max} at T_{max}) and secondly, the inflection point of the curve (C_{inpt} at T_{inpt}). The inflection point of the curve describes the point where the algebraic sign of the curvature changes. T_{inpt} is equal to two times T_{max} . Thus, The twofold of the observed T_{max} value can be used as a threshold of time points to be included in the calculation of $\lambda(z)$. Then, within that range, we apply minimum AIC values to get best fit. It starts with the last three data points from the concentration-time profile, performing log-linear regression to calculate the slope of that tail portion of the concentration- time curve. And then the last 4 data points, the last 5 data points, on and on until it reaches the data point right after C_{max} . Thus, this method will not include the data point of (T_{max} , C_{max}).

description_TTTARS *Description for Two Times Tmax (TTT) and Adjusted R squared (ARS)*

Description

The TTT method is based on the Bateman function. The Bateman function has two outstanding points. First, the maximum of the curve (C_{max} at T_{max}) and secondly, the inflection point of the curve (C_{inpt} at T_{inpt}). The inflection point of the curve describes the point where the algebraic sign of the curvature changes. T_{inpt} is equal to two times T_{max} . Thus, The twofold of the observed T_{max} value can be used as a threshold of time points to be included in the calculation of $\lambda(z)$. Then, within that range, we apply maximum ARS values to get best fit. It starts with the last three data points from the concentration-time profile, performing log-linear regression to calculate the slope of that tail portion of the concentration- time curve. And then the last 4 data points, the last 5 data points, on and on until it reaches the data point right after C_{max} . Thus, this method will not include the data point of (T_{max} , C_{max}).

description_version *Description for version*

Description

Authors: Hsin-ya Lee, Yung-jin Lee 100, Shih-chuan 1st Rd. College of Pharmacy, Kaohsiung Medical University, Kaoshiung, Taiwan 80708 E-mail: hsinyalee@gmail.com, pkpd.taiwan@gmail.com
 bear's website: <http://pkpd.kmu.edu.tw/bear> R website: www.r-project.org

entertitle *enter Dose, xaxis and yaxis*

Description

enter Dose, xaxis and yaxis

entertitle.demo *enter Dose, xaxis and yaxis for demo file*

Description

enter Dose, xaxis and yaxis

go *List of bear Menu*

Description

You can use the functions as follows: 1.Single dose study 2.Multiple dose study

logdata *Sample size estimation for log transformation data for crossover and replicated study*

Description

This function will help you to choose appropriate sample size.

References

R-code based on SAS-code by (1) B. Jones and M.G. Kenward Design and Analysis of Cross-Over Trials Chapman & Hall/CRC, Boca Raton (2nd Edition 2000) (2) S. Patterson and B. Jones Bioequivalence and Statistics in Clinical Pharmacology Chapman & Hall/CRC, Boca Raton (2006) /*** WARNING : PROGRAM OFFERED FOR USE WITHOUT ANY GUARANTEES ***/ /*** NO LIABILITY IS ACCEPTED FOR ANY LOSS RESULTING FROM USE OF ***/ /*** THIS SET OF SAS INTRUCTIONS ***/ Modification of degrees of freedom according to a personal message by D. Hauschke (E-mail 2006-01-05) Tested in R-versions 2.6.2 / 2.5.1 / 1.9.1 / 1.9.0 2008-04-04 Sample size R-code was referred from Helmut Schuetz BEBAC - Consultancy services for Bioequivalence and Bioavailability Studies 1070 Vienna, Austria

Hauschke D, Steinijs VW, Diletti E and Burke M. Sample size determination for bioequivalence assessment using a multiplicative model. J. Pharmacokin. Biopharm. 20:557-561 (1992).

Multiple1menu *List of NCA non-replicated and replicated study*

Description

You can use the functions as follows: 1. NCA for non-replicated crossover study, 2. NCA for replicated crossover study,

Multipleaic *Akaike information criterion (AIC) method for multiple study*

Description

This method selects data points to estimate $\lambda(z)$ based on the minimum AIC values. It starts with the last three data points from the concentration-time profile, performing log-linear regression to calculate the slope of that tail portion of the concentration-time curve. And then the last 4 data points, the last 5 data points, on and on until it reaches the data point right after C_{max} . Thus, this method will not include the data point of (T_{max}, C_{max}) .

MultipleAICdemo *Akaike information criterion (AIC) method for demo function*

Description

This method selects data points to estimate $\lambda(z)$ based on the minimum AIC values. It starts with the last three data points from the concentration-time profile, performing log-linear regression to calculate the slope of that tail portion of the concentration-time curve. And then the last 4 data points, the last 5 data points, on and on until it reaches the data point right after C_{max} . Thus, this method will not include the data point of (T_{max}, C_{max}) .

MultipleAICoutput *Output for Adjusted R squared (ARS) method for multiple dose*

Description

We provides several txt outputs. 1. NCA PK.txt: $\rightarrow C_{max}, T_{max}, AUC_{0t}, AUC_{0inf}, AUC_{0t}/AUC_{0inf}, \ln(C_{max}), \ln(AUC_{0t}), \ln(AUC_{0inf}), MRT_{0inf}, T_{1/2}, V_d/F, \lambda z,$ and $Cl/F \rightarrow$ PK parameter summary (NCA outputs) 2. plots.pdf: individual linear and semilog plots, spaghetti plots, and mean conc. plots.
3. Statistical summaries.txt

MultipleAIC_BANOVA	<i>Akaike information criterion (AIC) method and ANOVA for multiple dose</i>
--------------------	--

Description

This method selects data points to estimate $\lambda(z)$ based on the minimum AIC values. It starts with the last three data points from the concentration-time profile, performing log-linear regression to calculate the slope of that tail portion of the concentration-time curve. And then the last 4 data points, the last 5 data points, on and on until it reaches the data point right after C_{max} . Thus, this method will not include the data point of (T_{max}, C_{max}) .

Statistical analysis (ANOVA(lm), 90CI...): With a two-treatment, two-period, two-sequence randomized crossover design, ANOVA statistical model includes factors of the following sources: sequence, subjects nested in sequences, period and treatment. ANOVA will be applied to obtain estimates for the adjusted differences between treatment means and the standard error associated with these differences. Log-transformed BA measures will also be analyzed.

MultipleARS	<i>Adjusted R squared (ARS) method for multiple dose</i>
-------------	--

Description

This method selects data points to estimate $\lambda(z)$ based on the maximum adjusted R squared values. It starts with the last three data points from the concentration-time course, performing log-linear regression to calculate the slope of that tail portion of the concentration-time curve. And then the last 4 data points, the last 5 data points, on and on until it excludes the data points of C_{max} . Thus, this method may exclude the data point of (T_{max}, C_{max}) . WNL v6. has the similar algorithms like this.

MultipleARS.BANOVA	<i>Adjusted R squared (ARS) method and ANOVA for multiple dose</i>
--------------------	--

Description

Adjusted R squared (ARS) method: This method selects data points to estimate $\lambda(z)$ based on the maximum adjusted R squared values. It starts with the last three data points from the concentration-time course, performing log-linear regression to calculate the slope of that tail portion of the concentration-time curve. And then the last 4 data points, the last 5 data points, on and on until it excludes the data points of C_{max} . Thus, this method may exclude the data point of (T_{max}, C_{max}) . WNL v6. has the similar algorithms like this.

Statistical analysis (ANOVA(lm), 90CI...): With a two-treatment, two-period, two-sequence randomized crossover design, ANOVA statistical model includes factors of the following sources: sequence, subjects nested in sequences, period and treatment. ANOVA will be applied to obtain estimates for the adjusted differences between treatment means and the standard error associated with these differences. Log-transformed BA measures will also be analyzed.

MultipleARSdemo *Adjusted R squared (ARS) method for demo function for multiple dose*

Description

This method selects data points to estimate $\lambda(z)$ based on the maximum adjusted R squared values. It starts with the last three data points from the concentration-time course, performing log-linear regression to calculate the slope of that tail portion of the concentration-time curve. And then the last 4 data points, the last 5 data points, on and on until it excludes the data points of C_{max} . Thus, this method may exclude the data point of (T_{max}, C_{max}) . WNL v6. has the similar algorithms like this.

MultipleARSoutput *Output for Adjusted R squared (ARS) method for multiple dose*

Description

We provides several txt outputs. 1. NCA PK.txt: $\rightarrow C_{max}, T_{max}, AUC_{0t}, AUC_{0inf}, AUC_{0t}/AUC_{0inf}, \ln(C_{max}), \ln(AUC_{0t}), \ln(AUC_{0inf}), MRT_{0inf}, T_{1/2}, V_d/F, \lambda z,$ and $Cl/F \rightarrow$ PK parameter summary (NCA outputs) 2. plots.pdf: individual linear and semilog plots, spaghetti plots, and mean conc. plots.
3. Statistical summaries.txt

MultipleBANOVA *Statistical analysis (ANOVA(lm), 90CI...)*

Description

With a two-treatment, two-period, two-sequence randomized crossover design, ANOVA statistical model includes factors of the following sources: sequence, subjects nested in sequences, period and treatment. ANOVA will be applied to obtain estimates for the adjusted differences between treatment means and the standard error associated with these differences. Log-transformed BA measures will also be analyzed.

We investigate the assessment of equivalence in intra-subject variabilities of bioavailability between formulations. Point and interval estimates for the inter-subject and intra-subject variabilities are also provided.

Moreover, a normal distribution test procedure based on Spearman's rank and Pearson's correlation coefficient and Pitman-Morgan's adjusted F test are provided.

Finally, several tests for assumptions using the inter-subject and intra-subject residuals are discussed. Statistical tests for detection of outlying subjects such as Hotelling T2 are presented.

References

1. Chow SC and Liu JP. Design and analysis of bioavailability- bioequivalence studies. Chapman & Hall/CRC, New York (2009).
2. Liu JP and Weng CS. Detection of outlying data in bioavailability- bioequivalence studies. Statist. Med. 10, 1375-1389 (1991).

MultipleBANOVAanalyze *ANOVA function for multiple dose*

Description

Data for ANOVA

References

Guidance for Industry. Statistical approaches to establishing Bioequivalence.

MultipleBANOVAcsv *choose separator and decimal type for multiple dose*

Description

Separator : comma, semicolon ,white space. Decimal: comma, point.

MultipleBANOVadata *Input/Edit data for ANOVA function for multiple dose*

Description

->subject no.(subj) ->drug 1:Reference 2:Test ->sequence (seq) Sequence 1:Reference->Test sequence Sequence 2:Test->Reference sequence ->period (prd) Period 1: first treatment period Period 2: second treatment period ->Css_max ->AUCss(tau): area under the predicted plasma concentration time curve (time = tau) ->LnCss_max: Log-transformed Cmax ->LnAUC0ss(tau): Log-transformed AUC0ss(tau)

MultipleBANOVAmenu *List of ANOVA Menu for multiple dose*

Description

You can use the functions as follows: 1.Statistical analysis (ANOVA(lm), 90CI...) 2.Demo for Statistical analysis (ANOVA(lm), 90CI...)

MultipleBANOVAoutput *Output of ANOVA function for multiple dose*

Description

We provides several txt outputs. 1.ANOVA stat.txt ->ANOVA:Css_max, AUCss(tau), lnCss_max, lnAUCss(tau) ->90CI: lnCss_max, lnAUCss(tau)

MultipleBANOVApplot *BANOVApplot for multiple dose*

Description

We provides several pdf. outputs about BANOVA plots for outlier detections. 1.Normal Probability Plot of lnCss_max (intrasubj) 2.Normal Probability Plot of lnCss_max (intersubj) 3.lnCss_max(expected value) vs. studentized residuals(intrasubj) 4.lnCss_max(expected value) vs. studentized residuals(intersubj) 5.Normal Probability Plot of lnAUCss(tau) (intrasubj) 6.Normal Probability Plot of lnAUCss(tau) (intersubj) 7.lnAUCss(tau)(expected value) vs. studentized residuals(intrasubj) 8.lnAUCss(tau)(expected value) vs. studentized residuals(intersubj)

Multipledata *Data for NCA analyze for multiple dose*

Description

The data give the data of subjects, drug, sequence, period, time, and concentration.

MultipldemoBANOVA *Statistical analysis (ANOVA(lm), 90CI...)for demo file*

Description

With a two-treatment, two-period, two-sequence randomized crossover design, ANOVA statistical model includes factors of the following sources: sequence, subjects nested in sequences, period and treatment. ANOVA will be applied to obtain estimates for the adjusted differences between treatment means and the standard error associated with these differences. Log-transformed BA measures will also be analyzed.

Multiplademomenu *menu for NCA demo file*

Description

lambda z est. from the exact 3 data points, lambda z est. with adjusted R sq. (ARS), lambda z est. with Akaike information criterion (AIC), lambda z est. with Two-Times-Tmax method (TTT), lambda z est. with TTT and ARS, lambda z est. with TTT and AIC

Multiplademomenu1 *menu for NCA demo file*

Description

lambda z est. from the exact 3 data points→ Statistical analysis, lambda z est. with adjusted R sq. (ARS)→ Statistical analysis, lambda z est. with Akaike information criterion (AIC)→ Statistical analysis, lambda z est. with Two-Times-Tmax method (TTT)→ Statistical analysis, lambda z est. with TTT and ARS→ Statistical analysis, lambda z est. with TTT and AIC→ Statistical analysis,

Multipliego *List of bear Menu*

Description

You can use the functions as follows: 1.Sample size estimation for average BE 2.Noncompartment Analysis (NCA) 3.ANOVA 4.NCA->ANOVA

Multiplemenu *List of NCA non-replicated and replicated study*

Description

You can use the functions as follows: 1. NCA for non-replicated crossover study, 2. NCA for replicated crossover study,

 MultiplNCA

Noncompartmental analysis (NCA) for multiple dose

Description

Noncompartmental analysis (NCA) approach is used to compute AUCs and the terminal elimination rate constants (λ_z) for drug plasma concentration. The linear trapezoidal method is applied to calculate AUC(time 0 to the last measurable Cp). The extrapolated AUC (from time of the last measurable Cp to time infinity) is equal to the last measurable Cp divided by λ_z .

 MultiplNCA.BANOVA

NCA and ANOVA for multiple dose

Description

Noncompartmental analysis (NCA) approach is used to compute AUCs and the terminal elimination rate constants (λ_z) for drug plasma concentration. The linear trapezoidal method is applied to calculate AUC(time 0 to the last measurable Cp). The extrapolated AUC (from time of the last measurable Cp to time infinity) is equal to the last measurable Cp divided by λ_z .

Statistical analysis (ANOVA(lm), 90CI...): With a two-treatment, two-period, two-sequence randomized crossover design, ANOVA statistical model includes factors of the following sources: sequence, subjects nested in sequences, period and treatment. ANOVA will be applied to obtain estimates for the adjusted differences between treatment means and the standard error associated with these differences. Log-transformed BA measures will also be analyzed.

 MultiplNCA.BANOVAanalyze

NCA and ANOVA function for multiple dose

Description

This function includes both NCAanalyze and BANOVAanalyze functions.

 MultiplNCA.BANOVAcsv *choose separator and decimal type for multiple dose*

Description

Separator : comma, semicolon ,white space. Decimal: comma, point.

MultipleNCA.BANOVAdata

Input/Edit data for NCA and ANOVA function for multiple dose

Description

Input/Edit Data ->subject no.(subj) ->sequence (seq) Sequence 1:Reference->Test sequence Sequence 2:Test->Reference sequence ->period (prd) Period 1: first treatment period Period 2: second treatment period ->time ->concentration (conc)

MultipleNCA.BANOVAmenu

List of NCA and ANOVA Menu for multiple dose

Description

You can use the functions as follows: 1.NCA->ANOVA 2.Run demo for NCA -> Statistical analysis

MultipleNCAanalyze

NCA analyze function for multiple dose

Description

We provide noncompartmental analysis (NCA) approach to compute AUCs and terminal elimination rate constant (kel) for plasma concentration. Here we provide six methods, exact 3 data points, ARS, TTT, AIC, TTT and ARS, and TTT and AIC.

MultipleNCAcsv

choose separator and decimal type for multiple dose

Description

Separator : comma, semicolon ,white space. Decimal: comma, point.

MultipleNCAdata *Input/Edit data for NCA function for multiple dose*

Description

Input/Edit Data ->subject no.(subj) ->sequence (seq) Sequence 1:Reference->Test sequence Sequence 2:Test->Reference sequence ->period (prd) Period 1: first treatment period Period 2: second treatment period ->time ->concentration (conc)

MultipleNCAdemo *Select the exact 3 data points(NCA) for demo function for multiple dose*

Description

Noncompartmental analysis (NCA) approach is used to compute AUCs and the terminal elimination rate constants (λ_z) for drug plasma concentration. The linear trapezoidal method is applied to calculate AUC(time 0 to the last measurable Cp). The extrapolated AUC (from time of the last measurable Cp to time infinity) is equal to the last measurable Cp divided by λ_z .

MultipleNCAdemo.BANOVA *Select the exact 3 data points(NCA) and ANOVA for demo function for multiple dose*

Description

Noncompartmental analysis (NCA) approach is used to compute AUCs and the terminal elimination rate constants (λ_z) for drug plasma concentration. The linear trapezoidal method is applied to calculate AUC(time 0 to the last measurable Cp). The extrapolated AUC (from time of the last measurable Cp to time infinity) is equal to the last measurable Cp divided by λ_z .

Statistical analysis (ANOVA(1m), 90CI...): With a two-treatment, two-period, two-sequence randomized crossover design, ANOVA statistical model includes factors of the following sources: sequence, subjects nested in sequences, period and treatment. ANOVA will be applied to obtain estimates for the adjusted differences between treatment means and the standard error associated with these differences. Log-transformed BA measures will also be analyzed.

MultipleNCAmenu *List of NCA 2x2x2 Menu for multiple dose*

Description

You can use the functions as follows: 1.multiple Dose 2.Demo for multiple Dose

MultipleNCAoutput *Output of NCA for multiple dose*

Description

We provides several txt outputs. 1. NCA PK.txt: →C_{ss}_max, T_{ss}_max, AUC_{ss}(tau), ln(C_{ss}_max), ln(AUC_{ss}(tau)), MRT_{ss}(tau), T1/2(z), Vd/F, lambda, Cl_{ss}/F, Cav and Fluctuation → PK parameter summary (NCA outputs) 2. plots.pdf: individual linear and semilog plots, spaghetti plots, and mean conc. plots.

3. Statistical summaries.txt

MultipleNCAplot *NCAplot for multiple dose*

Description

We provides several pdf. outputs about NCA plots. 1.Conc. vs. Time for individual subjects 2.Log10(Conc.) vs. Time for individual subjects 3.Test (.Conc. vs. Time) for all subjects 4.Reference (.Conc. vs. Time) for all subjects 5.Conc.(mean+-sd) vs Time for test and reference

MultipleNCAsave *Save NCA outputs for multiple dose*

Description

This function can save the results after NCA.

MultipleNCAselct *Select the exact 3 points in NCA for multiple dose*

Description

This function can help users select the exact 3 points for NCA function.

MultipleNCAselct.BANOVA
Select the exact 3 points in NCA and ANOVA for multiple dose

Description

This function can help users select the exact 3 points for NCA function.

MultipleNCAselctdemo *Select the exact 3 points in NCA for demo function for multiple dose*

Description

This function can help users select the exact 3 points for NCA function.

MultipleNCAselctdemo.BANOVA
Select the exact 3 points in NCA and ANOVA for demo function for multiple dose

Description

This function can help users select the exact 3 points for NCA function.

MultipleNCAselctsave *Select the exact 3 points in NCA and Save the data for multiple dose*

Description

This function can save the exact 3 points.

MultipleNCAselctsave.BANOVA
Select the exact 3 points in NCA and Save the data for multiple dose

Description

This function can save the exact 3 points.

Multiplentertitle *enter Dose, tau, time of last dose, xaxis and yaxis for multiple dose*

Description

enter Dose, tau, time of last dose, xaxis and yaxis

Multiplentertitle.demo

enter Dose, tau, time of last dose, xaxis and yaxis for multiple dose for demo file

Description

enter Dose, tau, time of last dose, xaxis and yaxis

MultipleParaAIC

Akaike information criterion (AIC) method for parallel with multiple dose study

Description

This method selects data points to estimate $\lambda(z)$ based on the minimum AIC values. It starts with the last three data points from the concentration-time profile, performing log-linear regression to calculate the slope of that tail portion of the concentration-time curve. And then the last 4 data points, the last 5 data points, on and on until it reaches the data point right after C_{max} . Thus, this method will not include the data point of (T_{max}, C_{max}) .

MultipleParaAIC.MIX

Akaike information criterion (AIC) method->statistics for parallel with multiple dose study

Description

This method selects data points to estimate $\lambda(z)$ based on the minimum AIC values. It starts with the last three data points from the concentration-time profile, performing log-linear regression to calculate the slope of that tail portion of the concentration-time curve. And then the last 4 data points, the last 5 data points, on and on until it reaches the data point right after C_{max} . Thus, this method will not include the data point of (T_{max}, C_{max}) .

MultipleParaAICdemo

Akaike information criterion (AIC) method for demo function for parallel with multiple dose study

Description

This method selects data points to estimate $\lambda(z)$ based on the minimum AIC values. It starts with the last three data points from the concentration-time profile, performing log-linear regression to calculate the slope of that tail portion of the concentration-time curve. And then the last 4 data points, the last 5 data points, on and on until it reaches the data point right after C_{max} . Thus, this method will not include the data point of (T_{max}, C_{max}) .

MultipleParaAICoutput *Output for Adjusted R squared (ARS) method for parallel with multiple dose study*

Description

We provides several txt outputs. 1. NCA PK.txt: ->Css_max, Tss_max, AUCss(tau), ln(Css_max), ln(AUCss(tau)), MRTss(tau), T1/2(z), Vd/F, lambda, Clss/F, Cav and Fluctuation -> PK parameter summary (NCA outputs) 2. plots.pdf: individual linear and semilog plots, spaghetti plots, and mean conc. plots.

3. Statistical summaries.txt

MultipleParaARS *Adjusted R squared (ARS) method for parallel with multiple dose study*

Description

This method selects data points to estimate lambda(z) based on the maximum adjustedR squared values. It starts with the last three data points from the concentration-time course, performing log-linear regression to calculate the slope of that tail portion of the concentration-time curve. And then the last 4 data points, the last 5 data points, on and on until it excludes the data points of Cmax. Thus, this method may exclude the data point of (Tmax, Cmax). WNL v6. has the similar algorithms like this.

MultipleParaARS.MIX *Adjusted R squared (ARS) method and lme for parallel with multiple dose study*

Description

Adjusted R squared (ARS) method: This method selects data points to estimate lambda(z) based on the maximum adjustedR squared values. It starts with the last three data points from the concentration-time course, performing log-linear regression to calculate the slope of that tail portion of the concentration-time curve. And then the last 4 data points, the last 5 data points, on and on until it excludes the data points of Cmax. Thus, this method may exclude the data point of (Tmax, Cmax). WNL v6. has the similar algorithms like this.

With a two-treatment, two-sequence, one-period, parallel design, bear deploys the linear mixed effect model (lme). The statistical model includes a factor regarding only one source of variation - treatment. There are no sources of variation associated with sequence or period because there are no sequences or periods in a parallel design. Moreover, lme in nlme package is used to obtain estimates for the adjusted differences between treatment means and the standard error. Log-transformed BA measures will also be analyzed.

MultipleParaARSDemo *Adjusted R squared (ARS) method for demo function for parallel with multiple dose study*

Description

This method selects data points to estimate $\lambda(z)$ based on the maximum adjusted R squared values. It starts with the last three data points from the concentration-time course, performing log-linear regression to calculate the slope of that tail portion of the concentration-time curve. And then the last 4 data points, the last 5 data points, on and on until it excludes the data points of C_{max} . Thus, this method may exclude the data point of (T_{max}, C_{max}) . WNL v6. has the similar algorithms like this.

MultipleParaARSOutput *Output for Adjusted R squared (ARS) method for parallel study*

Description

We provides several txt outputs. 1. NCA PK.txt: $\rightarrow C_{ss_max}$, T_{ss_max} , $AUC_{ss}(\tau)$, $\ln(C_{ss_max})$, $\ln(AUC_{ss}(\tau))$, $MRT_{ss}(\tau)$, $T_{1/2}(z)$, V_d/F , λ , Cl_{ss}/F , C_{av} and Fluctuation \rightarrow PK parameter summary (NCA outputs) 2. plots.pdf: individual linear and semilog plots, spaghetti plots, and mean conc. plots.

3. Statistical summaries.txt

MultipleParadata *Data for NCA analyze for parallel with multiple dose study*

Description

The data give the data of subjects, drug, time, and concentration.

MultipleParademomenu *menu for NCA demo file for parallel with multiple dose study*

Description

λ z est. from the exact 3 data points, λ z est. with adjusted R sq. (ARS), λ z est. with Akaike information criterion (AIC), λ z est. with Two-Times- T_{max} method (TTT), λ z est. with TTT and ARS, λ z est. with TTT and AIC

MultipleParademomenu1 *menu for NCA->Statistical analysis demo file for parallel with multiple dose study*

Description

lambda z est. from the exact 3 data points-> Statistical analysis, lambda z est. with adjusted R sq. (ARS)-> Statistical analysis, lambda z est. with Akaike information criterion (AIC)-> Statistical analysis, lambda z est. with Two-Times-Tmax method (TTT)-> Statistical analysis, lambda z est. with TTT and ARS-> Statistical analysis, lambda z est. with TTT and AIC-> Statistical analysis,

MultipleParademomIX *Statistical analysis (lme, 90CI...)for demo file for parallel with multiple dose study*

Description

Statistical analysis (lme, 90CI...): With a two-treatment, two-sequence, one-period, parallel design, bear deploys the linear mixed effect model (lme). The statistical model includes a factor regarding only one source of variation - treatment. There are no sources of variation associated with sequence or period because there are no sequences or periods in a parallel design. Moreover, lme in nlme package is used to obtain estimates for the adjusted differences between treatment means and the standard error. Log-transformed BA measures will also be analyzed.

MultipleParamenu *List of NCA 2x2x1 Menu for multiple dose*

Description

You can use the functions as follows: 1.run NCA 2.Demo for NCA

MultipleParaMIX *Statistical analysis (lme, 90CI...) for parallel with multiple dose study*

Description

With a two-treatment, two-sequence, one-period, parallel design, bear deploys the linear mixed effect model (lme). The statistical model includes a factor regarding only one source of variation - treatment. There are no sources of variation associated with sequence or period because there are no sequences or periods in a parallel design. Moreover, lme in nlme package is used to obtain estimates for the adjusted differences between treatment means and the standard error. Log-transformed BA measures will also be analyzed.

MultipleParaMIXanalyze

Split data to perform lme function for parallel with multiple dose study

Description

Split data for lme function

References

Guidance for Industry. Statistical approaches to establishing Bioequivalence.

MultipleParaMIXcsv

choose separator and decimal type for multiple dose

Description

Separator : comma, semicolon ,white space. Decimal: comma, point.

MultipleParaMIXdata

Input/Edit data for lme function for parallel with multiple dose study

Description

->subject no.(subj) ->drug 1:Reference 2:Test ->Css_max ->AUCss(tau): area under the predicted plasma concentration time curve (time = tau) ->LnCss_max: Log-transformed Cmax ->LnAUC0ss(tau): Log-transformed AUC0ss(tau)

MultipleParaMIXmenu

List of lme Menu for multiple dose

Description

You can use the functions as follows: 1.Statistical analysis (lme, 90CI...) 2.Demo for Statistical analysis (lme, 90CI...)

MultipleParaMIXoutput *Output of lme function for multiple dose*

Description

We provides several txt outputs. 1.lme stat.txt ->lme: C_{ss_max}, AUC_{ss(tau)}, lnC_{ss_max}, lnAUC_{ss(tau)}
 ->90CI: lnC_{ss_max}, lnAUC_{ss(tau)}

MultipleParaNCA *Noncompartmental analysis (NCA) for parallel with multiple dose study*

Description

Noncompartmental analysis (NCA) approach is used to compute AUCs and the terminal elimination rate constants (λz) for drug plasma concentration. The linear trapezoidal method is applied to calculate AUC(time 0 to the last measurable Cp). The extrapolated AUC (from time of the last measurable Cp to time infinity) is equal to the last measurable Cp divided by λz .

MultipleParaNCA.MIX *NCA and lme for parallel study for multiple dose*

Description

Noncompartmental analysis (NCA) approach is used to compute AUCs and the terminal elimination rate constants (λz) for drug plasma concentration. The linear trapezoidal method is applied to calculate AUC(time 0 to the last measurable Cp). The extrapolated AUC (from time of the last measurable Cp to time infinity) is equal to the last measurable Cp divided by λz .

Statistical analysis (lme, 90CI...): With a two-treatment, two-sequence, one-period, parallel design, bear deploys the linear mixed effect model (lme). The statistical model includes a factor regarding only one source of variation - treatment. There are no sources of variation associated with sequence or period because there are no sequences or periods in a parallel design. Moreover, lme in nlme package is used to obtain estimates for the adjusted differences between treatment means and the standard error. Log-transformed BA measures will also be analyzed.

MultipleParaNCA.MIXanalyze
NCA and lme function for multiple dose

Description

This function includes both NCA and lme functions.

MultipleParaNCA.MIXcsv

choose separator and decimal type for multiple dose

Description

Separator : comma, semicolon ,white space. Decimal: comma, point.

MultipleParaNCA.MIXdata

Input/Edit data for NCA and lme function for parallel with multiple dose study

Description

Input/Edit Data ->subject no.(subj) ->drug ref.: 1 test: 2 ->time ->concentration (conc)

MultipleParaNCA.MIXmenu

List of NCA and lme Menu for multiple dose

Description

You can use the functions as follows: 1.NCA->lme 2.Run demo for NCA -> Statistical analysis

MultipleParaNCAanalyze

NCA analyze function for parallel with multiple dose study

Description

We provide noncompartmental analysis (NCA) approach to compute AUCs and terminal elimination rate constant (kel) for plasma concentration. Here we provide six methods, exact 3 data points, ARS, TTT, AIC, TTT and ARS, and TTT and AIC.

MultipleParaNCAcsv

choose separator and decimal type

Description

Separator : comma, semicolon ,white space. Decimal: comma, point.

MultipleParaNCAdata *Input/Edit data for NCA function for parallel study*

Description

Input/Edit Data ->subject no.(subj) ->drug ->time ->concentration (conc)

MultipleParaNCAdemo *Select the exact 3 data points(NCA) for demo function for parallel study*

Description

Noncompartmental analysis (NCA) approach is used to compute AUCs and the terminal elimination rate constants (λz) for drug plasma concentration. The linear trapezoidal method is applied to calculate AUC(time 0 to the last measurable C_p). The extrapolated AUC (from time of the last measurable C_p to time infinity) is equal to the last measurable C_p divided by λz .

MultipleParaNCAdemo.MIX
Select the exact 3 data points(NCA) and lme for demo function

Description

Noncompartmental analysis (NCA) approach is used to compute AUCs and the terminal elimination rate constants (λz) for drug plasma concentration. The linear trapezoidal method is applied to calculate AUC(time 0 to the last measurable C_p). The extrapolated AUC (from time of the last measurable C_p to time infinity) is equal to the last measurable C_p divided by λz .

Statistical analysis (lme, 90CI...): With a two-treatment, two-sequence, one-period, parallel design, bear deploys the linear mixed effect model (lme). The statistical model includes a factor regarding only one source of variation - treatment. There are no sources of variation associated with sequence or period because there are no sequences or periods in a parallel design. Moreover, lme in nlme package is used to obtain estimates for the adjusted differences between treatment means and the standard error. Log-transformed BA measures will also be analyzed.

MultipleParaNCAoutput *Output of NCA for parallel study*

Description

We provides several txt outputs. 1. NCA PK.txt: -> C_{ss_max} , T_{ss_max} , $AUC_{ss}(\tau)$, $\ln(C_{ss_max})$, $\ln(AUC_{ss}(\tau))$, $MRT_{ss}(\tau)$, $T_{1/2}(z)$, V_d/F , λ , Cl_{ss}/F , C_{av} and Fluctuation -> PK parameter summary (NCA outputs) 2. plots.pdf: individual linear and semilog plots, spaghetti plots, and mean conc. plots.

3. Statistical summaries.txt

MultipleParaNCAselctdemo.MIX

Select the exact 3 points in NCA and lme for demo function (parallel study)

Description

This function can help users select the exact 3 points for NCA function.

MultipleParaNCAselctsave

Select the exact 3 points in NCA and Save the data for parallel study

Description

This function can save data of the exact 3 points.

MultipleParaNCAselctsave.MIX

Select the exact 3 points in NCA and Save the data

Description

This function can save the exact 3 points.

MultipleParaTTT

Two Times Tmax (TTT) method for parallel study

Description

The TTT method is based on the Bateman function. The Bateman function has two outstanding points. First, the maximum of the curve (C_{max} at T_{max}) and secondly, the inflection point of the curve (C_{inpt} at T_{inpt}). The inflection point of the curve describes the point where the algebraic sign of the curvature changes. T_{inpt} is equal to two times T_{max} . Thus, The twofold of the observed T_{max} value can be used as a threshold of time points to be included in the calculation of $\lambda(z)$.

References

Scheerans C, Derendorf H and C Kloft. Proposal for a Standardised Identification of the Mono-Exponential Terminal Phase for Orally Administered Drugs. *Biopharm Drug Dispos* 29, 145-157 (2008).

MultipleParaTTT.MIX *TTT and lme for parallel study*

Description

The TTT method is based on the Bateman function. The Bateman function has two outstanding points. First, the maximum of the curve (C_{max} at T_{max}) and secondly, the inflection point of the curve (C_{inpt} at T_{inpt}). The inflection point of the curve describes the point where the algebraic sign of the curvature changes. T_{inpt} is equal to two times T_{max} . Thus, The twofold of the observed T_{max} value can be used as a threshold of time points to be included in the calculation of $\lambda(z)$.

Statistical analysis (lme, 90CI...): With a two-treatment, two-sequence, one-period, parallel design, bear deploys the linear mixed effect model (lme). The statistical model includes a factor regarding only one source of variation - treatment. There are no sources of variation associated with sequence or period because there are no sequences or periods in a parallel design. Moreover, lme in nlme package is used to obtain estimates for the adjusted differences between treatment means and the standard error. Log-transformed BA measures will also be analyzed.

References

Scheerans C, Derendorf H and C Kloft. Proposal for a Standardised Identification of the Mono-Exponential Terminal Phase for Orally Administered Drugs. *Biopharm Drug Dispos* 29, 145-157 (2008).

MultipleParaTTTAIC *TTT and AIC for parallel study*

Description

The TTT method is based on the Bateman function. The Bateman function has two outstanding points. First, the maximum of the curve (C_{max} at T_{max}) and secondly, the inflection point of the curve (C_{inpt} at T_{inpt}). The inflection point of the curve describes the point where the algebraic sign of the curvature changes. T_{inpt} is equal to two times T_{max} . Thus, The twofold of the observed T_{max} value can be used as a threshold of time points to be included in the calculation of $\lambda(z)$. Then, within that range, we apply minimum AIC values to get best fit. It starts with the last three data points from the concentration-time profile, performing log-linear regression to calculate the slope of that tail portion of the concentration- time curve. And then the last 4 data points, the last 5 data points, on and on until it reaches the data point right after C_{max} . Thus, this method will not include the data point of (T_{max} , C_{max}).

References

Scheerans C, Derendorf H and C Kloft. Proposal for a Standardised Identification of the Mono-Exponential Terminal Phase for Orally Administered Drugs. *Biopharm Drug Dispos* 29, 145-157 (2008).

MultipleParaTTTAIC.MIX

TTT ,AIC and lme for parallel study

Description

The TTT method is based on the Bateman function. The Bateman function has two outstanding points. First, the maximum of the curve (Cmax at Tmax) and secondly, the inflection point of the curve (Cinpt at Tinpt). The inflection point of the curve describes the point where the algebraic sign of the curvature changes. Tinpt is equal to two times Tmax. Thus, The twofold of the observed Tmax value can be used as a threshold of time points to be included in the calculation of lambda(z). Then, within that range, we apply minimum AIC values to get best fit. It starts with the last three data points from the concentration-time profile, performing log-linear regression to calculate the slope of that tail portion of the concentration- time curve. And then the last 4 data points, the last 5 data points, on and on until it reaches the data point right after Cmax. Thus, this method will not include the data point of (Tmax, Cmax).

Statistical analysis (lme, 90CI...): With a two-treatment, two-sequence, one-period, parallel design, bear deploys the linear mixed effect model (lme). The statistical model includes a factor regarding only one source of variation - treatment. There are no sources of variation associated with sequence or period because there are no sequences or periods in a parallel design. Moreover, lme in nlme package is used to obtain estimates for the adjusted differences between treatment means and the standard error. Log-transformed BA measures will also be analyzed.

MultipleParaTTTAICdemo

TTT and AIC for demo function for parallel study

Description

The TTT method is based on the Bateman function. The Bateman function has two outstanding points. First, the maximum of the curve (Cmax at Tmax) and secondly, the inflection point of the curve (Cinpt at Tinpt). The inflection point of the curve describes the point where the algebraic sign of the curvature changes. Tinpt is equal to two times Tmax. Thus, The twofold of the observed Tmax value can be used as a threshold of time points to be included in the calculation of lambda(z). Then, within that range, we apply minimum AIC values to get best fit. It starts with the last three data points from the concentration-time profile, performing log-linear regression to calculate the slope of that tail portion of the concentration- time curve. And then the last 4 data points, the last 5 data points, on and on until it reaches the data point right after Cmax. Thus, this method will not include the data point of (Tmax, Cmax).

References

Scheerans C, Derendorf H and C Kloft. Proposal for a Standardised Identification of the Mono-Exponential Terminal Phase for Orally Administered Drugs. Biopharm Drug Dispos 29, 145-157 (2008).

MultipleParaTTTAICoutput

Output for TTT and AIC for parallel study

Description

We provides several txt outputs. 1. NCA PK.txt: ->C_{ss_max}, T_{ss_max}, AUC_{ss(tau)}, ln(C_{ss_max}), ln(AUC_{ss(tau)}), MRT_{ss(tau)}, T_{1/2(z)}, V_{d/F}, lambda, C_{lss/F}, C_{av} and Fluctuation -> PK parameter summary (NCA outputs) 2. plots.pdf: individual linear and semilog plots, spaghetti plots, and mean conc. plots.

3. Statistical summaries.txt

References

Scheerans C, Derendorf H and C Kloft. Proposal for a Standardised Identification of the Mono-Exponential Terminal Phase for Orally Administered Drugs. Biopharm Drug Dispos 29, 145-157 (2008).

MultipleParaTTTARS

TTT and ARS for parallel study

Description

The TTT method is based on the Bateman function. The Bateman function has two outstanding points. First, the maximum of the curve (C_{max} at T_{max}) and secondly, the inflection point of the curve (C_{inpt} at T_{inpt}). The inflection point of the curve describes the point where the algebraic sign of the curvature changes. T_{inpt} is equal to two times T_{max}. Thus, The twofold of the observed T_{max} value can be used as a threshold of time points to be included in the calculation of lambda(z). Then, within that range, we apply maximum ARS values to get best fit. It starts with the last three data points from the concentration-time profile, performing log-linear regression to calculate the slope of that tail portion of the concentration- time curve. And then the last 4 data points, the last 5 data points, on and on until it reaches the data point right after C_{max}. Thus, this method will not include the data point of (T_{max}, C_{max}).

References

Scheerans C, Derendorf H and C Kloft. Proposal for a Standardised Identification of the Mono-Exponential Terminal Phase for Orally Administered Drugs. Biopharm Drug Dispos 29, 145-157 (2008).

MultipleParaTTTARS.MIX

TTT ,ARS and lme for parallel study

Description

The TTT method is based on the Bateman function. The Bateman function has two outstanding points. First, the maximum of the curve (Cmax at Tmax) and secondly, the inflection point of the curve (Cinpt at Tinpt). The inflection point of the curve describes the point where the algebraic sign of the curvature changes. Tinpt is equal to two times Tmax. Thus, The twofold of the observed Tmax value can be used as a threshold of time points to be included in the calculation of lambda(z). Then, within that range, we apply maximum ARS values to get best fit. It starts with the last three data points from the concentration-time profile, performing log-linear regression to calculate the slope of that tail portion of the concentration- time curve. And then the last 4 data points, the last 5 data points, on and on until it reaches the data point right after Cmax. Thus, this method will not include the data point of (Tmax, Cmax).

Statistical analysis (lme, 90CI...): With a two-treatment, two-sequence, one-period, parallel design, we deploy the linear mixed effect model (lme). The statistical model includes a factor regarding only one source of variation - treatment. There are no sources of variation associated with sequence or period because there are no sequences or periods in a parallel design. Moreover, lme in nlme package is used to obtain estimates for the adjusted differences between treatment means and the standard error. Log-transformed BA measures will also be analyzed.

References

Scheerans C, Derendorf H and C Kloft. Proposal for a Standardised Identification of the Mono-Exponential Terminal Phase for Orally Administered Drugs. Biopharm Drug Dispos 29, 145-157 (2008).

MultipleParaTTTARSdemo

TTT and ARS for demo function for parallel study

Description

The TTT method is based on the Bateman function. The Bateman function has two outstanding points. First, the maximum of the curve (Cmax at Tmax) and secondly, the inflection point of the curve (Cinpt at Tinpt). The inflection point of the curve describes the point where the algebraic sign of the curvature changes. Tinpt is equal to two times Tmax. Thus, The twofold of the observed Tmax value can be used as a threshold of time points to be included in the calculation of lambda(z). Then, within that range, we apply maximum ARS values to get best fit. It starts with the last three data points from the concentration-time profile, performing log-linear regression to calculate the slope of that tail portion of the concentration- time curve. And then the last 4 data points, the last 5 data points, on and on until it reaches the data point right after Cmax. Thus, this method will not include the data point of (Tmax, Cmax).

References

Scheerans C, Derendorf H and C Kloft. Proposal for a Standardised Identification of the Mono-Exponential Terminal Phase for Orally Administered Drugs. Biopharm Drug Dispos 29, 145-157 (2008).

MultipleParaTTTARSoutput

Output for TTT and ARS for parallel study

Description

We provides several txt outputs. 1. NCA PK.txt: → Cmax, Tmax, AUC0t, AUC0inf, AUC0t/AUC0inf, ln(Cmax), ln(AUC0t), ln(AUC0inf), MRT0inf, T1/2, Vd/F, lambda z, and Cl/F → PK parameter summary (NCA outputs) 2. plots.pdf: individual linear and semilog plots, spaghetti plots, and mean conc. plots.

3. Statistical summaries.txt

References

Scheerans C, Derendorf H and C Kloft. Proposal for a Standardised Identification of the Mono-Exponential Terminal Phase for Orally Administered Drugs. Biopharm Drug Dispos 29, 145-157 (2008).

MultipleParaTTTdemo

Two Times Tmax (TTT) method for demo function for parallel study

Description

The TTT method is based on the Bateman function. The Bateman function has two outstanding points. First, the maximum of the curve (Cmax at Tmax) and secondly, the inflection point of the curve (Cinpt at Tinpt). The inflection point of the curve describes the point where the algebraic sign of the curvature changes. Tinpt is equal to two times Tmax. Thus, The twofold of the observed Tmax value can be used as a threshold of time points to be included in the calculation of lambda(z).

MultipleParaTTToutput

Output for Two Times Tmax (TTT) method for parallel study

Description

We provides several txt outputs. 1. NCA PK.txt: → C_{ss_max}, T_{ss_max}, AUC_{ss(tau)}, ln(C_{ss_max}), ln(AUC_{ss(tau)}), MRT_{ss(tau)}, T1/2(z), Vd/F, lambda, Cl_{ss/F}, Cav and Fluctuation → PK parameter summary (NCA outputs) 2. plots.pdf: individual linear and semilog plots, spaghetti plots, and mean conc. plots.

3. Statistical summaries.txt

Multipleplotsingle *plot individual data for crossover study*

Description

Plot for individual person for BA (conc vs. time) and ln(BA)(lnconc vs. time)

Multipleplotsingle.para
plot individual data for parallel study

Description

Plot for individual person for BA (conc vs. time) and ln(BA)(lnconc vs. time)

Multiplestat1menu *List of Statistical analysis non-replicated and replicated study*

Description

You can use the functions as follows: 1. Statistical analysis for non-replicated crossover study, 2. Statistical analysis for replicated crossover study,

Multiplestatmenu *List of NCA->statistics non-replicated and replicated study*

Description

You can use the functions as follows: 1. NCA for non-replicated crossover study, 2. NCA for replicated crossover study,

 MultipleTTT

Two Times Tmax (TTT) method

Description

The TTT method is based on the Bateman function. The Bateman function has two outstanding points. First, the maximum of the curve (C_{max} at T_{max}) and secondly, the inflection point of the curve (C_{inpt} at T_{inpt}). The inflection point of the curve describes the point where the algebraic sign of the curvature changes. T_{inpt} is equal to two times T_{max} . Thus, The twofold of the observed T_{max} value can be used as a threshold of time points to be included in the calculation of $\lambda(z)$.

References

Scheerans C, Derendorf H and C Kloft. Proposal for a Standardised Identification of the Mono-Exponential Terminal Phase for Orally Administered Drugs. *Biopharm Drug Dispos* 29, 145-157 (2008).

 MultipleTTT.BANOVA

TTT and ANOVA

Description

The TTT method is based on the Bateman function. The Bateman function has two outstanding points. First, the maximum of the curve (C_{max} at T_{max}) and secondly, the inflection point of the curve (C_{inpt} at T_{inpt}). The inflection point of the curve describes the point where the algebraic sign of the curvature changes. T_{inpt} is equal to two times T_{max} . Thus, The twofold of the observed T_{max} value can be used as a threshold of time points to be included in the calculation of $\lambda(z)$.

Statistical analysis (ANOVA(lm), 90CI...): With a two-treatment, two-period, two-sequence randomized crossover design, ANOVA statistical model includes factors of the following sources: sequence, subjects nested in sequences, period and treatment. ANOVA will be applied to obtain estimates for the adjusted differences between treatment means and the standard error associated with these differences. Log-transformed BA measures will also be analyzed.

References

Scheerans C, Derendorf H and C Kloft. Proposal for a Standardised Identification of the Mono-Exponential Terminal Phase for Orally Administered Drugs. *Biopharm Drug Dispos* 29, 145-157 (2008).

MultipleTTTAIC

*TTT and AIC***Description**

The TTT method is based on the Bateman function. The Bateman function has two outstanding points. First, the maximum of the curve (C_{max} at T_{max}) and secondly, the inflection point of the curve (C_{inpt} at T_{inpt}). The inflection point of the curve describes the point where the algebraic sign of the curvature changes. T_{inpt} is equal to two times T_{max} . Thus, The twofold of the observed T_{max} value can be used as a threshold of time points to be included in the calculation of $\lambda(z)$. Then, within that range, we apply minimum AIC values to get best fit. It starts with the last three data points from the concentration-time profile, performing log-linear regression to calculate the slope of that tail portion of the concentration- time curve. And then the last 4 data points, the last 5 data points, on and on until it reaches the data point right after C_{max} . Thus, this method will not include the data point of (T_{max} , C_{max}).

References

Scheerans C, Derendorf H and C Kloft. Proposal for a Standardised Identification of the Mono-Exponential Terminal Phase for Orally Administered Drugs. *Biopharm Drug Dispos* 29, 145-157 (2008).

MultipleTTTAIC.BANOVA *TTT ,AIC and ANOVA***Description**

The TTT method is based on the Bateman function. The Bateman function has two outstanding points. First, the maximum of the curve (C_{max} at T_{max}) and secondly, the inflection point of the curve (C_{inpt} at T_{inpt}). The inflection point of the curve describes the point where the algebraic sign of the curvature changes. T_{inpt} is equal to two times T_{max} . Thus, The twofold of the observed T_{max} value can be used as a threshold of time points to be included in the calculation of $\lambda(z)$. Then, within that range, we apply minimum AIC values to get best fit. It starts with the last three data points from the concentration-time profile, performing log-linear regression to calculate the slope of that tail portion of the concentration- time curve. And then the last 4 data points, the last 5 data points, on and on until it reaches the data point right after C_{max} . Thus, this method will not include the data point of (T_{max} , C_{max}).

Statistical analysis (ANOVA(lm), 90CI...): With a two-treatment, two-period, two-sequence randomized crossover design, ANOVA statistical model includes factors of the following sources: sequence, subjects nested in sequences, period and treatment. ANOVA will be applied to obtain estimates for the adjusted differences between treatment means and the standard error associated with these differences. Log-transformed BA measures will also be analyzed.

MultipleTTTAICdemo *TTT and AIC for demo function*

Description

The TTT method is based on the Bateman function. The Bateman function has two outstanding points. First, the maximum of the curve (C_{max} at T_{max}) and secondly, the inflection point of the curve (C_{inpt} at T_{inpt}). The inflection point of the curve describes the point where the algebraic sign of the curvature changes. T_{inpt} is equal to two times T_{max} . Thus, The twofold of the observed T_{max} value can be used as a threshold of time points to be included in the calculation of $\lambda(z)$. Then, within that range, we apply minimum AIC values to get best fit. It starts with the last three data points from the concentration-time profile, performing log-linear regression to calculate the slope of that tail portion of the concentration-time curve. And then the last 4 data points, the last 5 data points, on and on until it reaches the data point right after C_{max} . Thus, this method will not include the data point of (T_{max} , C_{max}).

References

Scheerans C, Derendorf H and C Kloft. Proposal for a Standardised Identification of the Mono-Exponential Terminal Phase for Orally Administered Drugs. *Biopharm Drug Dispos* 29, 145-157 (2008).

MultipleTTTAICoutput *Output for TTT and AIC*

Description

We provides several txt outputs. 1. NCA PK.txt: $\rightarrow C_{ss_max}$, T_{ss_max} , $AUC_{ss}(\tau)$, $\ln(C_{ss_max})$, $\ln(AUC_{ss}(\tau))$, $MRT_{ss}(\tau)$, $T_{1/2}(z)$, V_d/F , λ , Cl_{ss}/F , C_{av} and Fluctuation \rightarrow PK parameter summary (NCA outputs) 2. plots.pdf: individual linear and semilog plots, spaghetti plots, and mean conc. plots.

3. Statistical summaries.txt

References

Scheerans C, Derendorf H and C Kloft. Proposal for a Standardised Identification of the Mono-Exponential Terminal Phase for Orally Administered Drugs. *Biopharm Drug Dispos* 29, 145-157 (2008).

MultipleTTTARS

TTT and ARS

Description

The TTT method is based on the Bateman function. The Bateman function has two outstanding points. First, the maximum of the curve (C_{max} at T_{max}) and secondly, the inflection point of the curve (C_{inpt} at T_{inpt}). The inflection point of the curve describes the point where the algebraic sign of the curvature changes. T_{inpt} is equal to two times T_{max} . Thus, The twofold of the observed T_{max} value can be used as a threshold of time points to be included in the calculation of $\lambda(z)$. Then, within that range, we apply maximum ARS values to get best fit. It starts with the last three data points from the concentration-time profile, performing log-linear regression to calculate the slope of that tail portion of the concentration- time curve. And then the last 4 data points, the last 5 data points, on and on until it reaches the data point right after C_{max} . Thus, this method will not include the data point of (T_{max} , C_{max}).

References

Scheerans C, Derendorf H and C Kloft. Proposal for a Standardised Identification of the Mono-Exponential Terminal Phase for Orally Administered Drugs. *Biopharm Drug Dispos* 29, 145-157 (2008).

MultipleTTTARS.BANOVA *TTT,ARS and ANOVA*

Description

The TTT method is based on the Bateman function. The Bateman function has two outstanding points. First, the maximum of the curve (C_{max} at T_{max}) and secondly, the inflection point of the curve (C_{inpt} at T_{inpt}). The inflection point of the curve describes the point where the algebraic sign of the curvature changes. T_{inpt} is equal to two times T_{max} . Thus, The twofold of the observed T_{max} value can be used as a threshold of time points to be included in the calculation of $\lambda(z)$. Then, within that range, we apply maximum ARS values to get best fit. It starts with the last three data points from the concentration-time profile, performing log-linear regression to calculate the slope of that tail portion of the concentration- time curve. And then the last 4 data points, the last 5 data points, on and on until it reaches the data point right after C_{max} . Thus, this method will not include the data point of (T_{max} , C_{max}).

Statistical analysis (ANOVA(lm), 90CI...): With a two-treatment, two-period, two-sequence randomized crossover design, ANOVA statistical model includes factors of the following sources: sequence, subjects nested in sequences, period and treatment. ANOVA will be applied to obtain estimates for the adjusted differences between treatment means and the standard error associated with these differences. Log-transformed BA measures will also be analyzed.

References

Scheerans C, Derendorf H and C Kloft. Proposal for a Standardised Identification of the Mono-Exponential Terminal Phase for Orally Administered Drugs. Biopharm Drug Dispos 29, 145-157 (2008).

MultipleTTTARSdemo *TTT and ARS for demo function*

Description

The TTT method is based on the Bateman function. The Bateman function has two outstanding points. First, the maximum of the curve (C_{max} at T_{max}) and secondly, the inflection point of the curve (C_{inpt} at T_{inpt}). The inflection point of the curve describes the point where the algebraic sign of the curvature changes. T_{inpt} is equal to two times T_{max} . Thus, The twofold of the observed T_{max} value can be used as a threshold of time points to be included in the calculation of $\lambda(z)$. Then, within that range, we apply maximum ARS values to get best fit. It starts with the last three data points from the concentration-time profile, performing log-linear regression to calculate the slope of that tail portion of the concentration-time curve. And then the last 4 data points, the last 5 data points, on and on until it reaches the data point right after C_{max} . Thus, this method will not include the data point of (T_{max} , C_{max}).

References

Scheerans C, Derendorf H and C Kloft. Proposal for a Standardised Identification of the Mono-Exponential Terminal Phase for Orally Administered Drugs. Biopharm Drug Dispos 29, 145-157 (2008).

MultipleTTTARSoutput *Output for TTT and ARS*

Description

We provides several txt outputs. 1. NCA PK.txt: $\rightarrow C_{ss_max}$, T_{ss_max} , $AUC_{ss}(\tau)$, $\ln(C_{ss_max})$, $\ln(AUC_{ss}(\tau))$, $MRT_{ss}(\tau)$, $T_{1/2}(z)$, V_d/F , λ , Cl_{ss}/F , C_{av} and Fluctuation \rightarrow PK parameter summary (NCA outputs) 2. plots.pdf: individual linear and semilog plots, spaghetti plots, and mean conc. plots.

3. Statistical summaries.txt

References

Scheerans C, Derendorf H and C Kloft. Proposal for a Standardised Identification of the Mono-Exponential Terminal Phase for Orally Administered Drugs. Biopharm Drug Dispos 29, 145-157 (2008).

MultipleTTTdemo

Two Times Tmax (TTT) method for demo function

Description

The TTT method is based on the Bateman function. The Bateman function has two outstanding points. First, the maximum of the curve (C_{max} at T_{max}) and secondly, the inflection point of the curve (C_{inpt} at T_{inpt}). The inflection point of the curve describes the point where the algebraic sign of the curvature changes. T_{inpt} is equal to two times T_{max} . Thus, The twofold of the observed T_{max} value can be used as a threshold of time points to be included in the calculation of $\lambda(z)$.

MultipleTTToutput

Output for Two Times Tmax (TTT) method

Description

We provides several txt outputs. 1. NCA PK.txt: $\rightarrow C_{ss_max}$, T_{ss_max} , $AUC_{ss}(\tau)$, $\ln(C_{ss_max})$, $\ln(AUC_{ss}(\tau))$, $MRT_{ss}(\tau)$, $T_{1/2}(z)$, V_d/F , λ , Cl_{ss}/F , C_{av} and Fluctuation \rightarrow PK parameter summary (NCA outputs) 2. plots.pdf: individual linear and semilog plots, spaghetti plots, and mean conc. plots.

3. Statistical summaries.txt

NCA

Noncompartmental analysis (NCA)

Description

Noncompartmental analysis (NCA) approach is used to compute AUCs and the terminal elimination rate constants (λz) for drug plasma concentration. The linear trapezoidal method is applied to calculate $AUC(\text{time } 0 \text{ to the last measurable } C_p)$. The extrapolated AUC (from time of the last measurable C_p to time infinity) is equal to the last measurable C_p divided by λz .

 NCA.BANOVA

NCA and ANOVA

Description

Noncompartmental analysis (NCA) approach is used to compute AUCs and the terminal elimination rate constants (λ_z) for drug plasma concentration. The linear trapezoidal method is applied to calculate AUC(time 0 to the last measurable C_p). The extrapolated AUC (from time of the last measurable C_p to time infinity) is equal to the last measurable C_p divided by λ_z .

Statistical analysis (ANOVA(lm), 90CI...): With a two-treatment, two-period, two-sequence randomized crossover design, ANOVA statistical model includes factors of the following sources: sequence, subjects nested in sequences, period and treatment. ANOVA will be applied to obtain estimates for the adjusted differences between treatment means and the standard error associated with these differences. Log-transformed BA measures will also be analyzed.

 NCA.BANOVAanalyze

NCA and ANOVA function

Description

This function includes both NCAanalyze and BANOVAanalyze functions.

 NCA.BANOVAcsv

choose separator and decimal type

Description

Separator : comma, semicolon ,white space. Decimal: comma, point.

 NCA.BANOVAdata

Input/Edit data for NCA and ANOVA function

Description

Input/Edit Data ->subject no.(subj) ->sequence (seq) Sequence 1:Reference->Test sequence Sequence 2:Test->Reference sequence ->period (prd) Period 1: first treatment period Period 2: second treatment period ->time ->concentration (conc)

NCA.BANOVAmenu *List of NCA and ANOVA Menu*

Description

You can use the functions as follows: 1.NCA→ANOVA 2.Run demo for NCA → Statistical analysis

NCAanalyze *NCA analyze function*

Description

We provide noncompartmental analysis (NCA) approach to compute AUCs and terminal elimination rate constant (k_{el}) for plasma concentration. Here we provide six methods, exact 3 data points, ARS, TTT, AIC, TTT and ARS, and TTT and AIC.

NCAcsv *choose separator and decimal type*

Description

Separator : comma, semicolon ,white space. Decimal: comma, point.

NCAdata *Input/Edit data for NCA function*

Description

Input/Edit Data ->subject no.(subj) ->sequence (seq) Sequence 1:Reference→Test sequence Sequence 2:Test→Reference sequence ->period (prd) Period 1: first treatment period Period 2: second treatment period ->time ->concentration (conc)

NCAdemo *Select the exact 3 data points(NCA) for demo function*

Description

Noncompartmental analysis (NCA) approach is used to compute AUCs and the terminal elimination rate constants (λ_z) for drug plasma concentration. The linear trapezoidal method is applied to calculate AUC(time 0 to the last measurable C_p). The extrapolated AUC (from time of the last measurable C_p to time infinity) is equal to the last measurable C_p divided by λ_z .

 NCAdemo.BANOVA

Select the exact 3 data points(NCA) and ANOVA for demo function

Description

Noncompartmental analysis (NCA) approach is used to compute AUCs and the terminal elimination rate constants (λ_z) for drug plasma concentration. The linear trapezoidal method is applied to calculate AUC(time 0 to the last measurable C_p). The extrapolated AUC (from time of the last measurable C_p to time infinity) is equal to the last measurable C_p divided by λ_z .

Statistical analysis (ANOVA(lm), 90CI...): With a two-treatment, two-period, two-sequence randomized crossover design, ANOVA statistical model includes factors of the following sources: sequence, subjects nested in sequences, period and treatment. ANOVA will be applied to obtain estimates for the adjusted differences between treatment means and the standard error associated with these differences. Log-transformed BA measures will also be analyzed.

 NCAmenu

List of NCA 2x2x2 Menu

Description

You can use the functions as follows: 1.Single Dose 2.Demo for Single Dose

 NCAoutput

Output of NCA

Description

We provides several txt outputs. 1. NCA PK.txt: \rightarrow C_{max} , T_{max} , AUC_{0t} , AUC_{0inf} , AUC_{0t}/AUC_{0inf} , $\ln(C_{max})$, $\ln(AUC_{0t})$, $\ln(AUC_{0inf})$, MRT_{0inf} , $T_{1/2}$, V_d/F , λ_z , and $Cl/F \rightarrow$ PK parameter summary (NCA outputs) 2. plots.pdf: individual linear and semilog plots, spaghetti plots, and mean conc. plots.

3. Statistical summaries.txt

 NCAplot

NCAplot

Description

We provides several pdf. outputs about NCA plots. 1.Conc. vs. Time for individual subjects 2.Log10(Conc.) vs. Time for individual subjects 3.Test (.Conc. vs. Time) for all subjects 4.Reference (.Conc. vs. Time) for all subjects 5.Conc.(mean+sd) vs Time for test and reference

NCAsave	<i>Save NCA outputs</i>
---------	-------------------------

Description

This function can save the results after NCA.

NCAsselect	<i>Select the exact 3 points in NCA</i>
------------	---

Description

This function can help users select the exact 3 points for NCA function.

NCAsselect.BANOVA	<i>Select the exact 3 points in NCA and ANOVA</i>
-------------------	---

Description

This function can help users select the exact 3 points for NCA function.

NCAsselectdemo	<i>Select the exact 3 points in NCA for demo function</i>
----------------	---

Description

This function can help users select the exact 3 points for NCA function.

NCAsselectdemo.BANOVA	<i>Select the exact 3 points in NCA and ANOVA for demo function</i>
-----------------------	---

Description

This function can help users select the exact 3 points for NCA function.

NCAselectsave	<i>Select the exact 3 points in NCA and Save the data</i>
---------------	---

Description

This function can save the exact 3 points.

NCAselectsave.BANOVA	<i>Select the exact 3 points in NCA and Save the data</i>
----------------------	---

Description

This function can save the exact 3 points.

ParaAIC	<i>Akaike information criterion (AIC) method for parallel study</i>
---------	---

Description

This method selects data points to estimate $\lambda(z)$ based on the minimum AIC values. It starts with the last three data points from the concentration-time profile, performing log-linear regression to calculate the slope of that tail portion of the concentration-time curve. And then the last 4 data points, the last 5 data points, on and on until it reaches the data point right after C_{max} . Thus, this method will not include the data point of (T_{max}, C_{max}) .

ParaAIC.MIX	<i>Akaike information criterion (AIC) method->statistics for parallel study</i>
-------------	--

Description

This method selects data points to estimate $\lambda(z)$ based on the minimum AIC values. It starts with the last three data points from the concentration-time profile, performing log-linear regression to calculate the slope of that tail portion of the concentration-time curve. And then the last 4 data points, the last 5 data points, on and on until it reaches the data point right after C_{max} . Thus, this method will not include the data point of (T_{max}, C_{max}) .

ParaAICdemo	<i>Akaike information criterion (AIC) method for demo function for parallel study</i>
-------------	---

Description

This method selects data points to estimate $\lambda(z)$ based on the minimum AIC values. It starts with the last three data points from the concentration-time profile, performing log-linear regression to calculate the slope of that tail portion of the concentration-time curve. And then the last 4 data points, the last 5 data points, on and on until it reaches the data point right after C_{max} . Thus, this method will not include the data point of (T_{max}, C_{max}) .

ParaAICoutput	<i>Output for Adjusted R squared (ARS) method for parallel study</i>
---------------	--

Description

We provides several txt outputs. 1. NCA PK.txt: $\rightarrow C_{max}, T_{max}, AUC_{0t}, AUC_{0inf}, AUC_{0t}/AUC_{0inf}, \ln(C_{max}), \ln(AUC_{0t}), \ln(AUC_{0inf}), MRT_{0inf}, T_{1/2}, V_d/F, \lambda z,$ and $Cl/F \rightarrow$ PK parameter summary (NCA outputs) 2. plots.pdf: individual linear and semilog plots, spaghetti plots, and mean conc. plots.

3. Statistical summaries.txt

ParaARS	<i>Adjusted R squared (ARS) method for parallel study</i>
---------	---

Description

This method selects data points to estimate $\lambda(z)$ based on the maximum adjusted R squared values. It starts with the last three data points from the concentration-time course, performing log-linear regression to calculate the slope of that tail portion of the concentration-time curve. And then the last 4 data points, the last 5 data points, on and on until it excludes the data points of C_{max} . Thus, this method may exclude the data point of (T_{max}, C_{max}) . WNL v6. has the similar algorithms like this.

 ParaARS.MIX

Adjusted R squared (ARS) method and lme for parallel study

Description

Adjusted R squared (ARS) method: This method selects data points to estimate $\lambda(z)$ based on the maximum adjusted R squared values. It starts with the last three data points from the concentration-time course, performing log-linear regression to calculate the slope of that tail portion of the concentration-time curve. And then the last 4 data points, the last 5 data points, on and on until it excludes the data points of C_{max} . Thus, this method may exclude the data point of (T_{max}, C_{max}) . WNL v6. has the similar algorithms like this.

With a two-treatment, two-sequence, one-period, parallel design, R uses the linear mixed effect model (lme). The statistical model includes a factor regarding only one source of variation - treatment. There are no sources of variation associated with sequence or period because there are no sequences or periods in a parallel design. Moreover, lme in nlme package is used to obtain estimates for the adjusted differences between treatment means and the standard error. Log-transformed BA measures will also be analyzed.

 ParaARSDemo

Adjusted R squared (ARS) method for demo function for parallel study

Description

This method selects data points to estimate $\lambda(z)$ based on the maximum adjusted R squared values. It starts with the last three data points from the concentration-time course, performing log-linear regression to calculate the slope of that tail portion of the concentration-time curve. And then the last 4 data points, the last 5 data points, on and on until it excludes the data points of C_{max} . Thus, this method may exclude the data point of (T_{max}, C_{max}) . WNL v6. has the similar algorithms like this.

 ParaARSoutput

Output for Adjusted R squared (ARS) method for parallel study

Description

We provide several txt outputs. 1. NCA PK.txt: $\rightarrow C_{max}, T_{max}, AUC_{0t}, AUC_{0inf}, AUC_{0t}/AUC_{0inf}, \ln(C_{max}), \ln(AUC_{0t}), \ln(AUC_{0inf}), MRT_{0inf}, T_{1/2}, V_d/F, \lambda z,$ and $CI/F \rightarrow$ PK parameter summary (NCA outputs) 2. plots.pdf: individual linear and semilog plots, spaghetti plots, and mean conc. plots.

3. Statistical summaries.txt

Paradata	<i>Sample size estimation for log transformation data for parallel study</i>
----------	--

Description

This function will help you to choose appropriate sample size.

References

1. Hauschke D, Steinijans VW, Diletti E and Burke M. Sample size determination for bioequivalence assessment using a multiplicative model. *J. Pharmacokin. Biopharm.* 20:557-561 (1992).
2. Julious SA. Tutorial in biostatistics: Sample sizes for clinical trials with normal data. *Statist. Med.* 23:1921-1986 (2004)

Parademomenu	<i>menu for NCA demo file for parallel study</i>
--------------	--

Description

lambda z est. from the exact 3 data points, lambda z est. with adjusted R sq. (ARS), lambda z est. with Akaike information criterion (AIC), lambda z est. with Two-Times-Tmax method (TTT), lambda z est. with TTT and ARS, lambda z est. with TTT and AIC

Parademomenu1	<i>menu for NCA->Statistical analysis demo file for parallel study</i>
---------------	---

Description

lambda z est. from the exact 3 data points-> Statistical analysis, lambda z est. with adjusted R sq. (ARS)-> Statistical analysis, lambda z est. with Akaike information criterion (AIC)-> Statistical analysis, lambda z est. with Two-Times-Tmax method (TTT)-> Statistical analysis, lambda z est. with TTT and ARS-> Statistical analysis, lambda z est. with TTT and AIC-> Statistical analysis,

ParademoMIX	<i>Statistical analysis (lme, 90CI...)for demo file for parallel study</i>
-------------	--

Description

Statistical analysis (lme, 90CI...): With a two-treatment, two-sequence, one-period, parallel design, bear deploys the linear mixed effect model (lme). The statistical model includes a factor regarding only one source of variation - treatment. There are no sources of variation associated with sequence or period because there are no sequences or periods in a parallel design. Moreover, lme in nlme package is used to obtain estimates for the adjusted differences between treatment means and the standard error. Log-transformed BA measures will also be analyzed.

Paralleldata	<i>Data for NCA analyze for parallel study</i>
--------------	--

Description

The data give the data of subjects, drug, time, and concentration.

Paramenu	<i>List of NCA 2x2x1 Menu</i>
----------	-------------------------------

Description

You can use the functions as follows: 1.run NCA 2.Demo for NCA

ParaMIX	<i>Statistical analysis (lme, 90CI...) for parallel study</i>
---------	---

Description

With a two-treatment, two-sequence, one-period, parallel design, bear deploys the linear mixed effect model (lme). The statistical model includes a factor regarding only one source of variation - treatment. There are no sources of variation associated with sequence or period because there are no sequences or periods in a parallel design. Moreover, lme in nlme package is used to obtain estimates for the adjusted differences between treatment means and the standard error. Log-transformed BA measures will also be analyzed.

ParaMIXanalyze	<i>Split data to perform lme function for parallel study</i>
----------------	--

Description

Split data for lme function

References

Guidance for Industry. Statistical approaches to establishing Bioequivalence.

ParaMIXcsv *choose separator and decimal type*

Description

Separator : comma, semicolon ,white space. Decimal: comma, point.

ParaMIXdata *Input/Edit data for lme function for parallel study*

Description

->subject no.(subj) ->drug 1:Reference 2:Test ->Cmax ->AUC0t: area under the predicted plasma concentration time curve for test data. (time = 0 to t) ->AUC0INF: area under the predicted plasma concentration time curve for test data. (time = 0 to infinity) ->LnCmax: Log-transformed Cmax ->LnAUC0t: Log-transformed AUC0t ->LnAUC0INF: Log-transformed AUC0INF

ParaMIXmenu *List of lme Menu*

Description

You can use the functions as follows: 1.Statistical analysis (lme, 90CI...) 2.Demo for Statistical analysis (lme, 90CI...)

ParaMIXoutput *Output of lme function*

Description

We provides several txt outputs. 1.lme stat.txt ->lme:Cmax, AUC0t, AUC0inf, ln(Cmax), ln(AUC0t), ln(AUC0inf) ->90CI: ln(Cmax), ln(AUC0t), and ln(AUC0inf)

ParaNCA *Noncompartmental analysis (NCA) for parallel study*

Description

Noncompartmental analysis (NCA) approach is used to compute AUCs and the terminal elimination rate constants (λ_z) for drug plasma concentration. The linear trapezoidal method is applied to calculate AUC(time 0 to the last measurable Cp). The extrapolated AUC (from time of the last measurable Cp to time infinity) is equal to the last measurable Cp divided by λ_z .

ParaNCA.MIX	<i>NCA and lme for parallel study</i>
-------------	---------------------------------------

Description

Noncompartmental analysis (NCA) approach is used to compute AUCs and the terminal elimination rate constants (λ_z) for drug plasma concentration. The linear trapezoidal method is applied to calculate AUC(time 0 to the last measurable C_p). The extrapolated AUC (from time of the last measurable C_p to time infinity) is equal to the last measurable C_p divided by λ_z .

Statistical analysis (lme, 90CI...): With a two-treatment, two-sequence, one-period, parallel design, bear deploys the linear mixed effect model (lme). The statistical model includes a factor regarding only one source of variation - treatment. There are no sources of variation associated with sequence or period because there are no sequences or periods in a parallel design. Moreover, lme in nlme package is used to obtain estimates for the adjusted differences between treatment means and the standard error. Log-transformed BA measures will also be analyzed.

ParaNCA.MIXanalyze	<i>NCA and lme function</i>
--------------------	-----------------------------

Description

This function includes both NCA and lme functions.

ParaNCA.MIXcsv	<i>choose separator and decimal type</i>
----------------	--

Description

Separator : comma, semicolon ,white space. Decimal: comma, point.

ParaNCA.MIXdata	<i>Input/Edit data for NCA and lme function for parallel study</i>
-----------------	--

Description

Input/Edit Data ->subject no.(subj) ->drug ref.: 1 test: 2 ->time ->concentration (conc)

ParaNCA.MIXmenu	<i>List of NCA and lme Menu</i>
-----------------	---------------------------------

Description

You can use the functions as follows: 1.NCA->lme 2.Run demo for NCA -> Statistical analysis

ParaNCAanalyze	<i>NCA analyze function for parallel study</i>
----------------	--

Description

We provide noncompartmental analysis (NCA) approach to compute AUCs and terminal elimination rate constant (k_{el}) for plasma concentration. Here we provide six methods, exact 3 data points, ARS, TTT, AIC, TTT and ARS, and TTT and AIC.

ParaNCAcsv	<i>choose separator and decimal type</i>
------------	--

Description

Separator : comma, semicolon ,white space. Decimal: comma, point.

ParaNCAdata	<i>Input/Edit data for NCA function for parallel study</i>
-------------	--

Description

Input/Edit Data ->subject no.(subj) ->drug ->time ->concentration (conc)

ParaNCAdemo	<i>Select the exact 3 data points(NCA) for demo function for parallel study</i>
-------------	---

Description

Noncompartmental analysis (NCA) approach is used to compute AUCs and the terminal elimination rate constants (λ_z) for drug plasma concentration. The linear trapezoidal method is applied to calculate AUC(time 0 to the last measurable C_p). The extrapolated AUC (from time of the last measurable C_p to time infinity) is equal to the last measurable C_p divided by λ_z .

ParaNCAdemo.MIX	<i>Select the exact 3 data points(NCA) and lme for demo function</i>
-----------------	--

Description

Noncompartmental analysis (NCA) approach is used to compute AUCs and the terminal elimination rate constants (λ_z) for drug plasma concentration. The linear trapezoidal method is applied to calculate AUC(time 0 to the last measurable C_p). The extrapolated AUC (from time of the last measurable C_p to time infinity) is equal to the last measurable C_p divided by λ_z .

Statistical analysis (lme, 90CI...): With a two-treatment, two-sequence, one-period, parallel design, bear deploys the linear mixed effect model (lme). The statistical model includes a factor regarding only one source of variation - treatment. There are no sources of variation associated with sequence or period because there are no sequences or periods in a parallel design. Moreover, lme in nlme package is used to obtain estimates for the adjusted differences between treatment means and the standard error. Log-transformed BA measures will also be analyzed.

ParaNCAoutput	<i>Output of NCA for parallel study</i>
---------------	---

Description

We provides several txt outputs. 1. NCA PK.txt: $\rightarrow C_{max}$, T_{max} , AUC_{0t} , AUC_{0inf} , AUC_{0t}/AUC_{0inf} , $\ln(C_{max})$, $\ln(AUC_{0t})$, $\ln(AUC_{0inf})$, MRT_{0inf} , $T_{1/2}$, V_d/F , λ_z , and $Cl/F \rightarrow$ PK parameter summary (NCA outputs) 2. plots.pdf: individual linear and semilog plots, spaghetti plots, and mean conc. plots.

3. Statistical summaries.txt

ParaNCApplot	<i>NCAplot for parallel study</i>
--------------	-----------------------------------

Description

We provides several pdf. outputs about NCA plots. 1.Conc. vs. Time for individual subjects 2.Log10(Conc.) vs. Time for individual subjects 3.Test (.Conc. vs. Time) for all subjects 4.Reference (.Conc. vs. Time) for all subjects 5.Conc.(mean \pm sd) vs Time for test and reference

ParaNCAsave	<i>Save NCA outputs for parallel study</i>
-------------	--

Description

This function can save the results after NCA.

ParaNCAselct	<i>Select the exact 3 points in NCA for parallel study</i>
--------------	--

Description

This function can help users select the exact 3 points for NCA function.

ParaNCAselct.MIX	<i>Select the exact 3 points in NCA and lme for parallel study</i>
------------------	--

Description

This function can help users select the exact 3 points for NCA function.

ParaNCAselctdemo	<i>Select the exact 3 points in NCA for demo function for parallel study</i>
------------------	--

Description

This function can help users select the exact 3 points for NCA function.

ParaNCAselctdemo.MIX	<i>Select the exact 3 points in NCA and lme for demo function (parallel study)</i>
----------------------	--

Description

This function can help users select the exact 3 points for NCA function.

ParaNCAselctsave	<i>Select the exact 3 points in NCA and Save the data for parallel study</i>
------------------	--

Description

This function can save data of the exact 3 points.

ParaNCAselctsave.MIX *Select the exact 3 points in NCA and Save the data*

Description

This function can save the exact 3 points.

ParaTTT *Two Times Tmax (TTT) method for parallel study*

Description

The TTT method is based on the Bateman function. The Bateman function has two outstanding points. First, the maximum of the curve (Cmax at Tmax) and secondly, the inflection point of the curve (Cinpt at Tinpt). The inflection point of the curve describes the point where the algebraic sign of the curvature changes. Tinpt is equal to two times Tmax. Thus, The twofold of the observed Tmax value can be used as a threshold of time points to be included in the calculation of lambda(z).

References

Scheerans C, Derendorf H and C Kloft. Proposal for a Standardised Identification of the Mono-Exponential Terminal Phase for Orally Administered Drugs. *Biopharm Drug Dispos* 29, 145-157 (2008).

ParaTTT.MIX *TTT and lme for parallel study*

Description

The TTT method is based on the Bateman function. The Bateman function has two outstanding points. First, the maximum of the curve (Cmax at Tmax) and secondly, the inflection point of the curve (Cinpt at Tinpt). The inflection point of the curve describes the point where the algebraic sign of the curvature changes. Tinpt is equal to two times Tmax. Thus, The twofold of the observed Tmax value can be used as a threshold of time points to be included in the calculation of lambda(z).

Statistical analysis (lme, 90CI...): With a two-treatment, two-sequence, one-period, parallel design, bear deploys the linear mixed effect model (lme). The statistical model includes a factor regarding only one source of variation - treatment. There are no sources of variation associated with sequence or period because there are no sequences or periods in a parallel design. Moreover, lme in nlme package is used to obtain estimates for the adjusted differences between treatment means and the standard error. Log-transformed BA measures will also be analyzed.

References

Scheerans C, Derendorf H and C Kloft. Proposal for a Standardised Identification of the Mono-Exponential Terminal Phase for Orally Administered Drugs. *Biopharm Drug Dispos* 29, 145-157 (2008).

 ParaTTTAIC

TTT and AIC for parallel study

Description

The TTT method is based on the Bateman function. The Bateman function has two outstanding points. First, the maximum of the curve (C_{max} at T_{max}) and secondly, the inflection point of the curve (C_{inpt} at T_{inpt}). The inflection point of the curve describes the point where the algebraic sign of the curvature changes. T_{inpt} is equal to two times T_{max} . Thus, The twofold of the observed T_{max} value can be used as a threshold of time points to be included in the calculation of $\lambda(z)$. Then, within that range, we apply minimum AIC values to get best fit. It starts with the last three data points from the concentration-time profile, performing log-linear regression to calculate the slope of that tail portion of the concentration- time curve. And then the last 4 data points, the last 5 data points, on and on until it reaches the data point right after C_{max} . Thus, this method will not include the data point of (T_{max} , C_{max}).

References

Scheerans C, Derendorf H and C Kloft. Proposal for a Standardised Identification of the Mono-Exponential Terminal Phase for Orally Administered Drugs. *Biopharm Drug Dispos* 29, 145-157 (2008).

 ParaTTTAIC.MIX

TTT ,AIC and lme for parallel study

Description

The TTT method is based on the Bateman function. The Bateman function has two outstanding points. First, the maximum of the curve (C_{max} at T_{max}) and secondly, the inflection point of the curve (C_{inpt} at T_{inpt}). The inflection point of the curve describes the point where the algebraic sign of the curvature changes. T_{inpt} is equal to two times T_{max} . Thus, The twofold of the observed T_{max} value can be used as a threshold of time points to be included in the calculation of $\lambda(z)$. Then, within that range, we apply minimum AIC values to get best fit. It starts with the last three data points from the concentration-time profile, performing log-linear regression to calculate the slope of that tail portion of the concentration- time curve. And then the last 4 data points, the last 5 data points, on and on until it reaches the data point right after C_{max} . Thus, this method will not include the data point of (T_{max} , C_{max}).

Statistical analysis (lme, 90CI...): With a two-treatment, two-sequence, one-period, parallel design, we employ the linear mixed effect model (lme). The statistical model includes a factor regarding only one source of variation - treatment. There are no sources of variation associated with sequence or period because there are no sequences or periods in a parallel design. Moreover, lme in nlme package is used to obtain estimates for the adjusted differences between treatment means and the standard error. Log-transformed BA measures will also be analyzed.

ParaTTTAICdemo

TTT and AIC for demo function for parallel study

Description

The TTT method is based on the Bateman function. The Bateman function has two outstanding points. First, the maximum of the curve (C_{max} at T_{max}) and secondly, the inflection point of the curve (C_{inpt} at T_{inpt}). The inflection point of the curve describes the point where the algebraic sign of the curvature changes. T_{inpt} is equal to two times T_{max} . Thus, The twofold of the observed T_{max} value can be used as a threshold of time points to be included in the calculation of $\lambda(z)$. Then, within that range, we apply minimum AIC values to get best fit. It starts with the last three data points from the concentration-time profile, performing log-linear regression to calculate the slope of that tail portion of the concentration-time curve. And then the last 4 data points, the last 5 data points, on and on until it reaches the data point right after C_{max} . Thus, this method will not include the data point of (T_{max} , C_{max}).

References

Scheerans C, Derendorf H and C Kloft. Proposal for a Standardised Identification of the Mono-Exponential Terminal Phase for Orally Administered Drugs. *Biopharm Drug Dispos* 29, 145-157 (2008).

ParaTTTAICoutput

Output for TTT and AIC for parallel study

Description

We provides several txt outputs. 1. NCA PK.txt: $\rightarrow C_{max}$, T_{max} , AUC_{0t} , AUC_{0inf} , AUC_{0t}/AUC_{0inf} , $\ln(C_{max})$, $\ln(AUC_{0t})$, $\ln(AUC_{0inf})$, MRT_{0inf} , $T_{1/2}$, V_d/F , λz , and $Cl/F \rightarrow$ PK parameter summary (NCA outputs) 2. plots.pdf: individual linear and semilog plots, spaghetti plots, and mean conc. plots.

3. Statistical summaries.txt

References

Scheerans C, Derendorf H and C Kloft. Proposal for a Standardised Identification of the Mono-Exponential Terminal Phase for Orally Administered Drugs. *Biopharm Drug Dispos* 29, 145-157 (2008).

Description

The TTT method is based on the Bateman function. The Bateman function has two outstanding points. First, the maximum of the curve (C_{max} at T_{max}) and secondly, the inflection point of the curve (C_{inpt} at T_{inpt}). The inflection point of the curve describes the point where the algebraic sign of the curvature changes. T_{inpt} is equal to two times T_{max} . Thus, The twofold of the observed T_{max} value can be used as a threshold of time points to be included in the calculation of $\lambda(z)$. Then, within that range, we apply maximum ARS values to get best fit. It starts with the last three data points from the concentration-time profile, performing log-linear regression to calculate the slope of that tail portion of the concentration- time curve. And then the last 4 data points, the last 5 data points, on and on until it reaches the data point right after C_{max} . Thus, this method will not include the data point of (T_{max} , C_{max}).

References

Scheerans C, Derendorf H and C Kloft. Proposal for a Standardised Identification of the Mono-Exponential Terminal Phase for Orally Administered Drugs. *Biopharm Drug Dispos* 29, 145-157 (2008).

Description

The TTT method is based on the Bateman function. The Bateman function has two outstanding points. First, the maximum of the curve (C_{max} at T_{max}) and secondly, the inflection point of the curve (C_{inpt} at T_{inpt}). The inflection point of the curve describes the point where the algebraic sign of the curvature changes. T_{inpt} is equal to two times T_{max} . Thus, The twofold of the observed T_{max} value can be used as a threshold of time points to be included in the calculation of $\lambda(z)$. Then, within that range, we apply maximum ARS values to get best fit. It starts with the last three data points from the concentration-time profile, performing log-linear regression to calculate the slope of that tail portion of the concentration- time curve. And then the last 4 data points, the last 5 data points, on and on until it reaches the data point right after C_{max} . Thus, this method will not include the data point of (T_{max} , C_{max}).

Statistical analysis (lme, 90CI...): With a two-treatment, two-sequence, one-period, parallel design, R deploys the linear mixed effect model (lme). The statistical model includes a factor regarding only one source of variation - treatment. There are no sources of variation associated with sequence or period because there are no sequences or periods in a parallel design. Moreover, lme in nlme package is used to obtain estimates for the adjusted differences between treatment means and the standard error. Log-transformed BA measures will also be analyzed.

References

Scheerans C, Derendorf H and C Kloft. Proposal for a Standardised Identification of the Mono-Exponential Terminal Phase for Orally Administered Drugs. *Biopharm Drug Dispos* 29, 145-157 (2008).

ParaTTTARsdemo

TTT and ARS for demo function for parallel study

Description

The TTT method is based on the Bateman function. The Bateman function has two outstanding points. First, the maximum of the curve (C_{max} at T_{max}) and secondly, the inflection point of the curve (C_{inpt} at T_{inpt}). The inflection point of the curve describes the point where the algebraic sign of the curvature changes. T_{inpt} is equal to two times T_{max} . Thus, The twofold of the observed T_{max} value can be used as a threshold of time points to be included in the calculation of $\lambda(z)$. Then, within that range, we apply maximum ARS values to get best fit. It starts with the last three data points from the concentration-time profile, performing log-linear regression to calculate the slope of that tail portion of the concentration-time curve. And then the last 4 data points, the last 5 data points, on and on until it reaches the data point right after C_{max} . Thus, this method will not include the data point of (T_{max} , C_{max}).

References

Scheerans C, Derendorf H and C Kloft. Proposal for a Standardised Identification of the Mono-Exponential Terminal Phase for Orally Administered Drugs. *Biopharm Drug Dispos* 29, 145-157 (2008).

ParaTTTARSoutput

Output for TTT and ARS for parallel study

Description

We provides several txt outputs. 1. NCA PK.txt: $\rightarrow C_{max}$, T_{max} , AUC_{0t} , AUC_{0inf} , AUC_{0t}/AUC_{0inf} , $\ln(C_{max})$, $\ln(AUC_{0t})$, $\ln(AUC_{0inf})$, MRT_{0inf} , $T_{1/2}$, V_d/F , λz , and $Cl/F \rightarrow$ PK parameter summary (NCA outputs) 2. plots.pdf: individual linear and semilog plots, spaghetti plots, and mean conc. plots.
3. Statistical summaries.txt

References

Scheerans C, Derendorf H and C Kloft. Proposal for a Standardised Identification of the Mono-Exponential Terminal Phase for Orally Administered Drugs. *Biopharm Drug Dispos* 29, 145-157 (2008).

 ParaTTTdemo

Two Times Tmax (TTT) method for demo function for parallel study

Description

The TTT method is based on the Bateman function. The Bateman function has two outstanding points. First, the maximum of the curve (Cmax at Tmax) and secondly, the inflection point of the curve (Cinpt at Tinpt). The inflection point of the curve describes the point where the algebraic sign of the curvature changes. Tinpt is equal to two times Tmax. Thus, The twofold of the observed Tmax value can be used as a threshold of time points to be included in the calculation of lambda(z).

 ParaTTToutput

Output for Two Times Tmax (TTT) method for parallel study

Description

We provides several txt outputs. 1. NCA PK.txt: -> Cmax, Tmax, AUC0t, AUC0inf, AUC0t/AUC0inf, ln(Cmax), ln(AUC0t), ln(AUC0inf), MRT0inf, T1/2, Vd/F, lambda, and Cl/F -> PK parameter summary (NCA outputs) 2. plots.pdf: individual linear and semilog plots, spaghetti plots, and mean conc. plots.
3. Statistical summaries.txt

 plotsingle

plot individual data for crossover study

Description

Plot for individual person for BA (conc vs. time) and ln(BA)(lnconc vs. time)

 plotsingle.para

plot individual data for parallel study

Description

Plot for individual person for BA (conc vs. time) and ln(BA)(lnconc vs. time)

plotsingle.Rep	<i>plot individual data for replicated study</i>
----------------	--

Description

Plot for individual person for BA (conc vs. time) and ln(BA)(lnconc vs. time)

prdcoun	<i>legends for plots</i>
---------	--------------------------

Description

The legend description for replicated study

Repaic	<i>Akaike information criterion (AIC) method for replicated study</i>
--------	---

Description

This method selects data points to estimate lambda(z) based on the minimum AIC values. It starts with the last three data points from the concentration-time profile, performing log-linear regression to calculate the slope of that tail portion of the concentration-time curve. And then the last 4 data points, the last 5 data points, on and on until it reaches the data point right after Cmax. Thus, this method will not include the data point of (Tmax, Cmax).

RepAIC.MIX	<i>Akaike information criterion (AIC) method->statistics for replicated study</i>
------------	--

Description

This method selects data points to estimate lambda(z) based on the minimum AIC values. It starts with the last three data points from the concentration-time profile, performing log-linear regression to calculate the slope of that tail portion of the concentration-time curve. And then the last 4 data points, the last 5 data points, on and on until it reaches the data point right after Cmax. Thus, this method will not include the data point of (Tmax, Cmax).

RepAICdemo	<i>Akaike information criterion (AIC) method for demo function for replicated study</i>
------------	---

Description

This method selects data points to estimate $\lambda(z)$ based on the minimum AIC values. It starts with the last three data points from the concentration-time profile, performing log-linear regression to calculate the slope of that tail portion of the concentration-time curve. And then the last 4 data points, the last 5 data points, on and on until it reaches the data point right after C_{max} . Thus, this method will not include the data point of (T_{max}, C_{max}) .

RepAICoutput	<i>Output for Adjusted R squared (ARS) method for replicated study</i>
--------------	--

Description

We provides several txt outputs. 1. NCA PK.txt: $\rightarrow C_{max}, T_{max}, AUC_{0t}, AUC_{0inf}, AUC_{0t}/AUC_{0inf}, \ln(C_{max}), \ln(AUC_{0t}), \ln(AUC_{0inf}), MRT_{0inf}, T_{1/2}, V_d/F, \lambda z,$ and $Cl/F \rightarrow$ PK parameter summary (NCA outputs) 2. plots.pdf: individual linear and semilog plots, spaghetti plots, and mean conc. plots.

3. Statistical summaries.txt

RepARS	<i>Adjusted R squared (ARS) method for replicated study</i>
--------	---

Description

This method selects data points to estimate $\lambda(z)$ based on the maximum adjusted R squared values. It starts with the last three data points from the concentration-time course, performing log-linear regression to calculate the slope of that tail portion of the concentration-time curve. And then the last 4 data points, the last 5 data points, on and on until it excludes the data points of C_{max} . Thus, this method may exclude the data point of (T_{max}, C_{max}) . WNL v6. has the similar algorithms like this.

 RepARS.MIX

Adjusted R squared (ARS) method and lme for replicated study

Description

Adjusted R squared (ARS) method: This method selects data points to estimate $\lambda(z)$ based on the maximum adjusted R squared values. It starts with the last three data points from the concentration-time course, performing log-linear regression to calculate the slope of that tail portion of the concentration-time curve. And then the last 4 data points, the last 5 data points, on and on until it excludes the data points of C_{max} . Thus, this method may exclude the data point of (T_{max}, C_{max}) . WNL v6. has the similar algorithms like this.

Statistical analysis (lme, 90CI...): With a two-treatment, more than two period, two-sequence randomized crossover design, linear mixed-effects model may be used. The lme in nlme package is used to obtain estimates for the adjusted differences between treatment means and the standard error associated with these differences. Log-transformed BA measures will also be analyzed.

 RepARSDemo

Adjusted R squared (ARS) method for demo function for replicated study

Description

This method selects data points to estimate $\lambda(z)$ based on the maximum adjusted R squared values. It starts with the last three data points from the concentration-time course, performing log-linear regression to calculate the slope of that tail portion of the concentration-time curve. And then the last 4 data points, the last 5 data points, on and on until it excludes the data points of C_{max} . Thus, this method may exclude the data point of (T_{max}, C_{max}) . WNL v6. has the similar algorithms like this.

 RepARSoutput

Output for Adjusted R squared (ARS) method for replicated study

Description

We provides several txt outputs. 1. NCA PK.txt: $\rightarrow C_{max}, T_{max}, AUC_{0t}, AUC_{0inf}, AUC_{0t}/AUC_{0inf}, \ln(C_{max}), \ln(AUC_{0t}), \ln(AUC_{0inf}), MRT_{0inf}, T_{1/2}, V_d/F, \lambda z,$ and $Cl/F \rightarrow$ PK parameter summary (NCA outputs) 2. plots.pdf: individual linear and semilog plots, spaghetti plots, and mean conc. plots.

3. Statistical summaries.txt

Repdemomenu *menu for NCA demo file for replicated study*

Description

lambda z est. from the exact 3 data points, lambda z est. with adjusted R sq. (ARS), lambda z est. with Akaike information criterion (AIC), lambda z est. with Two-Times-Tmax method (TTT), lambda z est. with TTT and ARS, lambda z est. with TTT and AIC

Repdemomenu1 *menu for NCA->Statistical analysis demo file for replicated study*

Description

lambda z est. from the exact 3 data points-> Statistical analysis, lambda z est. with adjusted R sq. (ARS)-> Statistical analysis, lambda z est. with Akaike information criterion (AIC)-> Statistical analysis, lambda z est. with Two-Times-Tmax method (TTT)-> Statistical analysis, lambda z est. with TTT and ARS-> Statistical analysis, lambda z est. with TTT and AIC-> Statistical analysis,

RepdemoMIX *Statistical analysis (lme, 90CI...)for demo file for replicated study*

Description

Statistical analysis (lme, 90CI...): With a two-treatment, more than two period, two-sequence randomized crossover design, linear mixed-effects model may be used. The lme in nlme package is used to obtain estimates for the adjusted differences between treatment means and the standard error associated with these differences. Log-transformed BA measures will also be analyzed.

Replicateddata *Data for NCA analyze for replicated study*

Description

The data give the data of subjects, drug, sequence, period, time, and concentration.

Repmenu	<i>List of NCA 2x2xn Menu</i>
---------	-------------------------------

Description

You can use the functions as follows: 1.run NCA 2.Demo for NCAe

RepMIX	<i>Statistical analysis (lme, 90CI...) for replicated study</i>
--------	---

Description

With a two-treatment, more than two period, two-sequence randomized crossover design, linear mixed-effects model may be used. The lme in nlme package is used to obtain estimates for the adjusted differences between treatment means and the standard error associated with these differences. Log-transformed BA measures will also be analyzed.

RepMIXanalyze	<i>Split data to perform lme function for replicated study</i>
---------------	--

Description

Split data for lme function

References

Guidance for Industry. Statistical approaches to establishing Bioequivalence.

RepMIXcsv	<i>choose separator and decimal type</i>
-----------	--

Description

Separator : comma, semicolon ,white space. Decimal: comma, point.

RepMIXdata

*Input/Edit data for lme function for replicated study***Description**

->subject no.(subj) ->drug 1:Reference 2:Test ->sequence (seq) Sequence 1:Reference->Test sequence Sequence 2:Test->Reference sequence ->period (prd) Period 1: first treatment period Period 2: second treatment period ->Cmax ->AUC0t: area under the predicted plasma concentration time curve for test data. (time = 0 to t) ->AUC0INF: area under the predicted plasma concentration time curve for test data. (time = 0 to infinity) ->LnCmax: Log-transformed Cmax ->LnAUC0t: Log-transformed AUC0t ->LnAUC0INF: Log-transformed AUC0INF

RepMIXmenu

*List of lme Menu***Description**

You can use the functions as follows: 1.Statistical analysis (lme, 90CI...) 2.Demo for Statistical analysis (lme, 90CI...)

RepMIXoutput

*Output of lme function***Description**

We provides several txt outputs. 1.lme stat.txt ->lme:Cmax, AUC0t, AUC0inf, ln(Cmax), ln(AUC0t), ln(AUC0inf) ->90CI: ln(Cmax), ln(AUC0t), and ln(AUC0inf)

RepNCA

*Noncompartmental analysis (NCA) for replicated study***Description**

Noncompartmental analysis (NCA) approach is used to compute AUCs and the terminal elimination rate constants (λ_z) for drug plasma concentration. The linear trapezoidal method is applied to calculate AUC(time 0 to the last measurable C_p). The extrapolated AUC (from time of the last measurable C_p to time infinity) is equal to the last measurable C_p divided by λ_z .

RepNCA.MIX	<i>NCA and lme for replicated study</i>
------------	---

Description

Noncompartmental analysis (NCA) approach is used to compute AUCs and the terminal elimination rate constants (λ_z) for drug plasma concentration. The linear trapezoidal method is applied to calculate AUC(time 0 to the last measurable Cp). The extrapolated AUC (from time of the last measurable Cp to time infinity) is equal to the last measurable Cp divided by λ_z .

Statistical analysis (lme, 90CI...): With a two-treatment, more than two period, two-sequence randomized crossover design, linear mixed-effects model may be used. The lme in nlme package is used to obtain estimates for the adjusted differences between treatment means and the standard error associated with these differences. Log-transformed BA measures will also be analyzed.

RepNCA.MIXanalyze	<i>NCA and lme function</i>
-------------------	-----------------------------

Description

This function includes both NCA and lme functions.

RepNCA.MIXcsv	<i>choose separator and decimal type</i>
---------------	--

Description

Separator : comma, semicolon ,white space. Decimal: comma, point.

RepNCA.MIXdata	<i>Input/Edit data for NCA and lme function for replicated study</i>
----------------	--

Description

Input/Edit Data ->subject no.(subj) ->sequence (seq) ->period (prd) Period 1: first treatmetn period
 Period 2: second treatmetn period ->drug ->time ->concentration (conc)

RepNCA.MIXmenu	<i>List of NCA and lme Menu</i>
----------------	---------------------------------

Description

You can use the functions as follows: 1.NCA→lme 2.Run demo for NCA → Statistical analysis

RepNCAanalyze	<i>NCA analyze function for replicated study</i>
---------------	--

Description

We provide noncompartmental analysis (NCA) approach to compute AUCs and terminal elimination rate constant (kel) for plasma concentration. Here we provide six methods, exact 3 data points, ARS, TTT, AIC, TTT and ARS, and TTT and AIC.

RepNCAcsv	<i>choose separator and decimal type</i>
-----------	--

Description

Separator : comma, semicolon ,white space. Decimal: comma, point.

RepNCAdata	<i>Input/Edit data for NCA function for replicated study</i>
------------	--

Description

Input/Edit Data ->subject no.(subj) ->sequence (seq) Sequence 1:Reference→Test sequence Sequence 2:Test→Reference sequence ->period (prd) Period 1: first treatment period Period 2: second treatment period ->drug ->time ->concentration (conc)

RepNCAdemo	<i>Select the exact 3 data points(NCA) for demo function for replicated study</i>
------------	---

Description

Noncompartmental analysis (NCA) approach is used to compute AUCs and the terminal elimination rate constants (λ_z) for drug plasma concentration. The linear trapezoidal method is applied to calculate AUC(time 0 to the last measurable Cp). The extrapolated AUC (from time of the last measurable Cp to time infinity) is equal to the last measurable Cp divided by λ_z .

 RepNCAdemo.MIX

Select the exact 3 data points(NCA) and lme for demo function

Description

Noncompartmental analysis (NCA) approach is used to compute AUCs and the terminal elimination rate constants (λz) for drug plasma concentration. The linear trapezoidal method is applied to calculate AUC(time 0 to the last measurable C_p). The extrapolated AUC (from time of the last measurable C_p to time infinity) is equal to the last measurable C_p divided by λz .

Statistical analysis (lme, 90CI...): With a two-treatment, more than two period, two-sequence randomized crossover design, linear mixed-effects model may be used. The lme in nlme package is used to obtain estimates for the adjusted differences between treatment means and the standard error associated with these differences. Log-transformed BA measures will also be analyzed.

RepNCAoutput

Output of NCA for replicated study

Description

We provides several txt outputs. 1. NCA PK.txt: $\rightarrow C_{max}$, T_{max} , AUC_{0t} , AUC_{0inf} , AUC_{0t}/AUC_{0inf} , $\ln(C_{max})$, $\ln(AUC_{0t})$, $\ln(AUC_{0inf})$, MRT_{0inf} , $T_{1/2}$, V_d/F , λz , and $CI/F \rightarrow$ PK parameter summary (NCA outputs) 2. plots.pdf: individual linear and semilog plots, spaghetti plots, and mean conc. plots.

3. Statistical summaries.txt

RepNCAsave

NCAplot for replicated study

Description

We provides several pdf. outputs about NCA plots. 1.Conc. vs. Time for individual subjects 2.Log10(Conc.) vs. Time for individual subjects 3.Test (.Conc. vs. Time) for all subjects 4.Reference (.Conc. vs. Time) for all subjects 5.Conc.(mean+-sd) vs Time for test and reference

RepNCAsave

Save NCA outputs for replicated study

Description

This function can save the results after NCA.

RepNCAselct	<i>Select the exact 3 points in NCA for replicated study</i>
-------------	--

Description

This function can help users select the exact 3 points for NCA function.

RepNCAselct.MIX	<i>Select the exact 3 points in NCA and lme for replicated study</i>
-----------------	--

Description

This function can help users select the exact 3 points for NCA function.

RepNCAselctdemo	<i>Select the exact 3 points in NCA for demo function for replicated study</i>
-----------------	--

Description

This function can help users select the exact 3 points for NCA function.

RepNCAselctdemo.MIX	<i>Select the exact 3 points in NCA and lme for demo function (replicated study)</i>
---------------------	--

Description

This function can help users select the exact 3 points for NCA function.

RepNCAselctsave	<i>Select the exact 3 points in NCA and Save the data for replicated study</i>
-----------------	--

Description

This function can save data of the exact 3 points.

RepNCAselctsave.MIX *Select the exact 3 points in NCA and Save the data*

Description

This function can save the exact 3 points.

RepTTT *Two Times Tmax (TTT) method for replicated study*

Description

The TTT method is based on the Bateman function. The Bateman function has two outstanding points. First, the maximum of the curve (C_{max} at T_{max}) and secondly, the inflection point of the curve (C_{inpt} at T_{inpt}). The inflection point of the curve describes the point where the algebraic sign of the curvature changes. T_{inpt} is equal to two times T_{max}. Thus, The twofold of the observed T_{max} value can be used as a threshold of time points to be included in the calculation of lambda(z).

References

Scheerans C, Derendorf H and C Kloft. Proposal for a Standardised Identification of the Mono-Exponential Terminal Phase for Orally Administered Drugs. *Biopharm Drug Dispos* 29, 145-157 (2008).

RepTTT.MIX *TTT and lme for replicated study*

Description

The TTT method is based on the Bateman function. The Bateman function has two outstanding points. First, the maximum of the curve (C_{max} at T_{max}) and secondly, the inflection point of the curve (C_{inpt} at T_{inpt}). The inflection point of the curve describes the point where the algebraic sign of the curvature changes. T_{inpt} is equal to two times T_{max}. Thus, The twofold of the observed T_{max} value can be used as a threshold of time points to be included in the calculation of lambda(z).

With a two-treatment, more than two period, two-sequence randomized crossover design, linear mixed-effects model may be used. The lme in nlme package is used to obtain estimates for the adjusted differences between treatment means and the standard error associated with these differences. Log-transformed BA measures will also be analyzed.

References

Scheerans C, Derendorf H and C Kloft. Proposal for a Standardised Identification of the Mono-Exponential Terminal Phase for Orally Administered Drugs. *Biopharm Drug Dispos* 29, 145-157 (2008).

 RepTTTAIC

TTT and AIC for replicated study

Description

The TTT method is based on the Bateman function. The Bateman function has two outstanding points. First, the maximum of the curve (C_{max} at T_{max}) and secondly, the inflection point of the curve (C_{inpt} at T_{inpt}). The inflection point of the curve describes the point where the algebraic sign of the curvature changes. T_{inpt} is equal to two times T_{max} . Thus, The twofold of the observed T_{max} value can be used as a threshold of time points to be included in the calculation of $\lambda(z)$. Then, within that range, we apply minimum AIC values to get best fit. It starts with the last three data points from the concentration-time profile, performing log-linear regression to calculate the slope of that tail portion of the concentration- time curve. And then the last 4 data points, the last 5 data points, on and on until it reaches the data point right after C_{max} . Thus, this method will not include the data point of (T_{max} , C_{max}).

References

Scheerans C, Derendorf H and C Kloft. Proposal for a Standardised Identification of the Mono-Exponential Terminal Phase for Orally Administered Drugs. *Biopharm Drug Dispos* 29, 145-157 (2008).

 RepTTTAIC.MIX

TTT ,AIC and lme for replicated study

Description

The TTT method is based on the Bateman function. The Bateman function has two outstanding points. First, the maximum of the curve (C_{max} at T_{max}) and secondly, the inflection point of the curve (C_{inpt} at T_{inpt}). The inflection point of the curve describes the point where the algebraic sign of the curvature changes. T_{inpt} is equal to two times T_{max} . Thus, The twofold of the observed T_{max} value can be used as a threshold of time points to be included in the calculation of $\lambda(z)$. Then, within that range, we apply minimum AIC values to get best fit. It starts with the last three data points from the concentration-time profile, performing log-linear regression to calculate the slope of that tail portion of the concentration- time curve. And then the last 4 data points, the last 5 data points, on and on until it reaches the data point right after C_{max} . Thus, this method will not include the data point of (T_{max} , C_{max}).

With a two-treatment, more than two period, two-sequence randomized crossover design, linear mixed-effects model may be used. The lme in nlme package is used to obtain estimates for the adjusted differences between treatment means and the standard error associated with these differences. Log-transformed BA measures will also be analyzed.

RepTTTAICdemo

TTT and AIC for demo function for replicated study

Description

The TTT method is based on the Bateman function. The Bateman function has two outstanding points. First, the maximum of the curve (C_{max} at T_{max}) and secondly, the inflection point of the curve (C_{inpt} at T_{inpt}). The inflection point of the curve describes the point where the algebraic sign of the curvature changes. T_{inpt} is equal to two times T_{max} . Thus, The twofold of the observed T_{max} value can be used as a threshold of time points to be included in the calculation of $\lambda(z)$. Then, within that range, we apply minimum AIC values to get best fit. It starts with the last three data points from the concentration-time profile, performing log-linear regression to calculate the slope of that tail portion of the concentration-time curve. And then the last 4 data points, the last 5 data points, on and on until it reaches the data point right after C_{max} . Thus, this method will not include the data point of (T_{max} , C_{max}).

References

Scheerans C, Derendorf H and C Kloft. Proposal for a Standardised Identification of the Mono-Exponential Terminal Phase for Orally Administered Drugs. *Biopharm Drug Dispos* 29, 145-157 (2008).

RepTTTAICoutput

Output for TTT and AIC for replicated study

Description

We provides several txt outputs. 1. NCA PK.txt: $\rightarrow C_{max}$, T_{max} , AUC_{0t} , AUC_{0inf} , AUC_{0t}/AUC_{0inf} , $\ln(C_{max})$, $\ln(AUC_{0t})$, $\ln(AUC_{0inf})$, MRT_{0inf} , $T_{1/2}$, V_d/F , λz , and $Cl/F \rightarrow$ PK parameter summary (NCA outputs) 2. plots.pdf: individual linear and semilog plots, spaghetti plots, and mean conc. plots.

3. Statistical summaries.txt

References

Scheerans C, Derendorf H and C Kloft. Proposal for a Standardised Identification of the Mono-Exponential Terminal Phase for Orally Administered Drugs. *Biopharm Drug Dispos* 29, 145-157 (2008).

 RepTTTARS

TTT and ARS for replicated study

Description

The TTT method is based on the Bateman function. The Bateman function has two outstanding points. First, the maximum of the curve (C_{max} at T_{max}) and secondly, the inflection point of the curve (C_{inpt} at T_{inpt}). The inflection point of the curve describes the point where the algebraic sign of the curvature changes. T_{inpt} is equal to two times T_{max} . Thus, The twofold of the observed T_{max} value can be used as a threshold of time points to be included in the calculation of $\lambda(z)$. Then, within that range, we apply maximum ARS values to get best fit. It starts with the last three data points from the concentration-time profile, performing log-linear regression to calculate the slope of that tail portion of the concentration-time curve. And then the last 4 data points, the last 5 data points, on and on until it reaches the data point right after C_{max} . Thus, this method will not include the data point of (T_{max} , C_{max}).

References

Scheerans C, Derendorf H and C Kloft. Proposal for a Standardised Identification of the Mono-Exponential Terminal Phase for Orally Administered Drugs. *Biopharm Drug Dispos* 29, 145-157 (2008).

 RepTTTARS.MIX

TTT ,ARS and lme for replicated study

Description

The TTT method is based on the Bateman function. The Bateman function has two outstanding points. First, the maximum of the curve (C_{max} at T_{max}) and secondly, the inflection point of the curve (C_{inpt} at T_{inpt}). The inflection point of the curve describes the point where the algebraic sign of the curvature changes. T_{inpt} is equal to two times T_{max} . Thus, The twofold of the observed T_{max} value can be used as a threshold of time points to be included in the calculation of $\lambda(z)$. Then, within that range, we apply maximum ARS values to get best fit. It starts with the last three data points from the concentration-time profile, performing log-linear regression to calculate the slope of that tail portion of the concentration-time curve. And then the last 4 data points, the last 5 data points, on and on until it reaches the data point right after C_{max} . Thus, this method will not include the data point of (T_{max} , C_{max}).

With a two-treatment, more than two period, two-sequence randomized crossover design, linear mixed-effects model may be used. The lme in nlme package is used to obtain estimates for the adjusted differences between treatment means and the standard error associated with these differences. Log-transformed BA measures will also be analyzed.

References

Scheerans C, Derendorf H and C Kloft. Proposal for a Standardised Identification of the Mono-Exponential Terminal Phase for Orally Administered Drugs. *Biopharm Drug Dispos* 29, 145-157 (2008).

RepTTTARSDemo

TTT and ARS for demo function for replicated study

Description

The TTT method is based on the Bateman function. The Bateman function has two outstanding points. First, the maximum of the curve (C_{max} at T_{max}) and secondly, the inflection point of the curve (C_{inpt} at T_{inpt}). The inflection point of the curve describes the point where the algebraic sign of the curvature changes. T_{inpt} is equal to two times T_{max} . Thus, The twofold of the observed T_{max} value can be used as a threshold of time points to be included in the calculation of $\lambda(z)$. Then, within that range, we apply maximum ARS values to get best fit. It starts with the last three data points from the concentration-time profile, performing log-linear regression to calculate the slope of that tail portion of the concentration-time curve. And then the last 4 data points, the last 5 data points, on and on until it reaches the data point right after C_{max} . Thus, this method will not include the data point of (T_{max} , C_{max}).

References

Scheerans C, Derendorf H and C Kloft. Proposal for a Standardised Identification of the Mono-Exponential Terminal Phase for Orally Administered Drugs. *Biopharm Drug Dispos* 29, 145-157 (2008).

RepTTTARSoutput

Output for TTT and ARS for replicated study

Description

We provides several txt outputs. 1. NCA PK.txt: $\rightarrow C_{max}$, T_{max} , AUC_{0t} , AUC_{0inf} , AUC_{0t}/AUC_{0inf} , $\ln(C_{max})$, $\ln(AUC_{0t})$, $\ln(AUC_{0inf})$, MRT_{0inf} , $T_{1/2}$, V_d/F , λz , and $Cl/F \rightarrow$ PK parameter summary (NCA outputs) 2. plots.pdf: individual linear and semilog plots, spaghetti plots, and mean conc. plots.
3. Statistical summaries.txt

References

Scheerans C, Derendorf H and C Kloft. Proposal for a Standardised Identification of the Mono-Exponential Terminal Phase for Orally Administered Drugs. *Biopharm Drug Dispos* 29, 145-157 (2008).

RepTTTdemo

*Two Times Tmax (TTT) method for demo function for replicated study***Description**

The TTT method is based on the Bateman function. The Bateman function has two outstanding points. First, the maximum of the curve (C_{max} at T_{max}) and secondly, the inflection point of the curve (C_{inpt} at T_{inpt}). The inflection point of the curve describes the point where the algebraic sign of the curvature changes. T_{inpt} is equal to two times T_{max} . Thus, The twofold of the observed T_{max} value can be used as a threshold of time points to be included in the calculation of $\lambda(z)$.

RepTTToutput

*Output for Two Times Tmax (TTT) method for replicated study***Description**

We provides several txt outputs. 1. NCA PK.txt: $\rightarrow C_{max}$, T_{max} , AUC_{0t} , AUC_{0inf} , AUC_{0t}/AUC_{0inf} , $\ln(C_{max})$, $\ln(AUC_{0t})$, $\ln(AUC_{0inf})$, MRT_{0inf} , $T_{1/2}$, V_d/F , λ , and $Cl/F \rightarrow$ PK parameter summary (NCA outputs) 2. plots.pdf: individual linear and semilog plots, spaghetti plots, and mean conc. plots.
3. Statistical summaries.txt

Singlego

*List of bear Menu***Description**

You can use the functions as follows: 1.Sample size estimation for average BE 2.Noncompartment Analysis (NCA) 3.ANOVA 4.NCA- \rightarrow ANOVA

sizemenu

*List of Sample size estimation Menu***Description**

You can use the functions as follows: 1.Sample size estimation (Raw data) 2.Sample size estimation (Log transformation) 3.Demo for sample size estimation (Raw data)

 stat1menu

List of Statistical analysis non-replicated and replicated study

Description

You can use the functions as follows: 1. Statistical analysis for non-replicated crossover study, 2. Statistical analysis for replicated crossover study,

 statmenu

List of Statistical analysis non-replicated and replicated study

Description

You can use the functions as follows: 1. Statistical analysis for non-replicated crossover study, 2. Statistical analysis for replicated crossover study,

 TotalSingledata

Data for NCA analyze

Description

The data give the data of subjects, drug, sequence, period, time, and concentration.

 TTT

Two Times Tmax (TTT) method

Description

The TTT method is based on the Bateman function. The Bateman function has two outstanding points. First, the maximum of the curve (C_{max} at T_{max}) and secondly, the inflection point of the curve (C_{inpt} at T_{inpt}). The inflection point of the curve describes the point where the algebraic sign of the curvature changes. T_{inpt} is equal to two times T_{max} . Thus, The twofold of the observed T_{max} value can be used as a threshold of time points to be included in the calculation of $\lambda(z)$.

References

Scheerans C, Derendorf H and C Kloft. Proposal for a Standardised Identification of the Mono-Exponential Terminal Phase for Orally Administered Drugs. Biopharm Drug Dispos 29, 145-157 (2008).

Description

The TTT method is based on the Bateman function. The Bateman function has two outstanding points. First, the maximum of the curve (C_{max} at T_{max}) and secondly, the inflection point of the curve (C_{inpt} at T_{inpt}). The inflection point of the curve describes the point where the algebraic sign of the curvature changes. T_{inpt} is equal to two times T_{max} . Thus, The twofold of the observed T_{max} value can be used as a threshold of time points to be included in the calculation of $\lambda(z)$.

Statistical analysis (ANOVA(lm), 90CI...): With a two-treatment, two-period, two-sequence randomized crossover design, ANOVA statistical model includes factors of the following sources: sequence, subjects nested in sequences, period and treatment. ANOVA will be applied to obtain estimates for the adjusted differences between treatment means and the standard error associated with these differences. Log-transformed BA measures will also be analyzed.

References

Scheerans C, Derendorf H and C Kloft. Proposal for a Standardised Identification of the Mono-Exponential Terminal Phase for Orally Administered Drugs. *Biopharm Drug Dispos* 29, 145-157 (2008).

Description

The TTT method is based on the Bateman function. The Bateman function has two outstanding points. First, the maximum of the curve (C_{max} at T_{max}) and secondly, the inflection point of the curve (C_{inpt} at T_{inpt}). The inflection point of the curve describes the point where the algebraic sign of the curvature changes. T_{inpt} is equal to two times T_{max} . Thus, The twofold of the observed T_{max} value can be used as a threshold of time points to be included in the calculation of $\lambda(z)$. Then, within that range, we apply minimum AIC values to get best fit. It starts with the last three data points from the concentration-time profile, performing log-linear regression to calculate the slope of that tail portion of the concentration-time curve. And then the last 4 data points, the last 5 data points, on and on until it reaches the data point right after C_{max} . Thus, this method will not include the data point of (T_{max} , C_{max}).

References

Scheerans C, Derendorf H and C Kloft. Proposal for a Standardised Identification of the Mono-Exponential Terminal Phase for Orally Administered Drugs. *Biopharm Drug Dispos* 29, 145-157 (2008).

TTTAIC.BANOVA

*TTT, AIC and ANOVA***Description**

The TTT method is based on the Bateman function. The Bateman function has two outstanding points. First, the maximum of the curve (Cmax at Tmax) and secondly, the inflection point of the curve (Cinpt at Tinpt). The inflection point of the curve describes the point where the algebraic sign of the curvature changes. Tinpt is equal to two times Tmax. Thus, The twofold of the observed Tmax value can be used as a threshold of time points to be included in the calculation of lambda(z). Then, within that range, we apply minimum AIC values to get best fit. It starts with the last three data points from the concentration-time profile, performing log-linear regression to calculate the slope of that tail portion of the concentration-time curve. And then the last 4 data points, the last 5 data points, on and on until it reaches the data point right after Cmax. Thus, this method will not include the data point of (Tmax, Cmax).

Statistical analysis (ANOVA(lm), 90CI...): With a two-treatment, two-period, two-sequence randomized crossover design, ANOVA statistical model includes factors of the following sources: sequence, subjects nested in sequences, period and treatment. ANOVA will be applied to obtain estimates for the adjusted differences between treatment means and the standard error associated with these differences. Log-transformed BA measures will also be analyzed.

TTTAICdemo

*TTT and AIC for demo function***Description**

The TTT method is based on the Bateman function. The Bateman function has two outstanding points. First, the maximum of the curve (Cmax at Tmax) and secondly, the inflection point of the curve (Cinpt at Tinpt). The inflection point of the curve describes the point where the algebraic sign of the curvature changes. Tinpt is equal to two times Tmax. Thus, The twofold of the observed Tmax value can be used as a threshold of time points to be included in the calculation of lambda(z). Then, within that range, we apply minimum AIC values to get best fit. It starts with the last three data points from the concentration-time profile, performing log-linear regression to calculate the slope of that tail portion of the concentration-time curve. And then the last 4 data points, the last 5 data points, on and on until it reaches the data point right after Cmax. Thus, this method will not include the data point of (Tmax, Cmax).

References

Scheerans C, Derendorf H and C Kloft. Proposal for a Standardised Identification of the Mono-Exponential Terminal Phase for Orally Administered Drugs. *Biopharm Drug Dispos* 29, 145-157 (2008).

TTTAICoutput

Output for TTT and AIC

Description

We provides several txt outputs. 1. NCA PK.txt: → Cmax, Tmax, AUC0t, AUC0inf, AUC0t/AUC0inf, ln(Cmax), ln(AUC0t), ln(AUC0inf), MRT0inf, T1/2, Vd/F, lambda z, and Cl/F → PK parameter summary (NCA outputs) 2. plots.pdf: individual linear and semilog plots, spaghetti plots, and mean conc. plots.

3. Statistical summaries.txt

References

Scheerans C, Derendorf H and C Kloft. Proposal for a Standardised Identification of the Mono-Exponential Terminal Phase for Orally Administered Drugs. Biopharm Drug Dispos 29, 145-157 (2008).

TTTARS

TTT and ARS

Description

The TTT method is based on the Bateman function. The Bateman function has two outstanding points. First, the maximum of the curve (Cmax at Tmax) and secondly, the inflection point of the curve (Cinpt at Tinpt). The inflection point of the curve describes the point where the algebraic sign of the curvature changes. Tinpt is equal to two times Tmax. Thus, The twofold of the observed Tmax value can be used as a threshold of time points to be included in the calculation of lambda(z). Then, within that range, we apply maximum ARS values to get best fit. It starts with the last three data points from the concentration-time profile, performing log-linear regression to calculate the slope of that tail portion of the concentration- time curve. And then the last 4 data points, the last 5 data points, on and on until it reaches the data point right after Cmax. Thus, this method will not include the data point of (Tmax, Cmax).

References

Scheerans C, Derendorf H and C Kloft. Proposal for a Standardised Identification of the Mono-Exponential Terminal Phase for Orally Administered Drugs. Biopharm Drug Dispos 29, 145-157 (2008).

 TTTARS.BANOVA

TTT ,ARS and ANOVA

Description

The TTT method is based on the Bateman function. The Bateman function has two outstanding points. First, the maximum of the curve (Cmax at Tmax) and secondly, the inflection point of the curve (Cinpt at Tinpt). The inflection point of the curve describes the point where the algebraic sign of the curvature changes. Tinpt is equal to two times Tmax. Thus, The twofold of the observed Tmax value can be used as a threshold of time points to be included in the calculation of lambda(z). Then, within that range, we apply maximum ARS values to get best fit. It starts with the last three data points from the concentration-time profile, performing log-linear regression to calculate the slope of that tail portion of the concentration- time curve. And then the last 4 data points, the last 5 data points, on and on until it reaches the data point right after Cmax. Thus, this method will not include the data point of (Tmax, Cmax).

Statistical analysis (ANOVA(lm), 90CI...): With a two-treatment, two-period, two-sequence randomized crossover design, ANOVA statistical model includes factors of the following sources: sequence, subjects nested in sequences, period and treatment. ANOVA will be applied to obtain estimates for the adjusted differences between treatment means and the standard error associated with these differences. Log-transformed BA measures will also be analyzed.

References

Scheerans C, Derendorf H and C Kloft. Proposal for a Standardised Identification of the Mono-Exponential Terminal Phase for Orally Administered Drugs. Biopharm Drug Dispos 29, 145-157 (2008).

 TTTARSdemo

TTT and ARS for demo function

Description

The TTT method is based on the Bateman function. The Bateman function has two outstanding points. First, the maximum of the curve (Cmax at Tmax) and secondly, the inflection point of the curve (Cinpt at Tinpt). The inflection point of the curve describes the point where the algebraic sign of the curvature changes. Tinpt is equal to two times Tmax. Thus, The twofold of the observed Tmax value can be used as a threshold of time points to be included in the calculation of lambda(z). Then, within that range, we apply maximum ARS values to get best fit. It starts with the last three data points from the concentration-time profile, performing log-linear regression to calculate the slope of that tail portion of the concentration- time curve. And then the last 4 data points, the last 5 data points, on and on until it reaches the data point right after Cmax. Thus, this method will not include the data point of (Tmax, Cmax).

References

Scheerans C, Derendorf H and C Kloft. Proposal for a Standardised Identification of the Mono-Exponential Terminal Phase for Orally Administered Drugs. *Biopharm Drug Dispos* 29, 145-157 (2008).

TTTARsOutput

Output for TTT and ARS

Description

We provides several txt outputs. 1. NCA PK.txt: \rightarrow Cmax, Tmax, AUC0t, AUC0inf, AUC0t/AUC0inf, $\ln(\text{Cmax})$, $\ln(\text{AUC0t})$, $\ln(\text{AUC0inf})$, MRT0inf, T1/2, Vd/F, lambda z, and CI/F \rightarrow PK parameter summary (NCA outputs) 2. plots.pdf: individual linear and semilog plots, spaghetti plots, and mean conc. plots.

3. Statistical summaries.txt

References

Scheerans C, Derendorf H and C Kloft. Proposal for a Standardised Identification of the Mono-Exponential Terminal Phase for Orally Administered Drugs. *Biopharm Drug Dispos* 29, 145-157 (2008).

TTTdemo

Two Times Tmax (TTT) method for demo function

Description

The TTT method is based on the Bateman function. The Bateman function has two outstanding points. First, the maximum of the curve (Cmax at Tmax) and secondly, the inflection point of the curve (Cinpt at Tinpt). The inflection point of the curve describes the point where the algebraic sign of the curvature changes. Tinpt is equal to two times Tmax. Thus, The twofold of the observed Tmax value can be used as a threshold of time points to be included in the calculation of lambda(z).

TTTdemo.BANOVA

*Two Times Tmax (TTT) method and ANOVA for demo function***Description**

The TTT method is based on the Bateman function. The Bateman function has two outstanding points. First, the maximum of the curve (Cmax at Tmax) and secondly, the inflection point of the curve (Cinpt at Tinpt). The inflection point of the curve describes the point where the algebraic sign of the curvature changes. Tinpt is equal to two times Tmax. Thus, The twofold of the observed Tmax value can be used as a threshold of time points to be included in the calculation of lambda(z).

Statistical analysis (ANOVA(lm), 90CI...): With a two-treatment, two-period, two-sequence randomized crossover design, ANOVA statistical model includes factors of the following sources: sequence, subjects nested in sequences, period and treatment. ANOVA will be applied to obtain estimates for the adjusted differences between treatment means and the standard error associated with these differences. Log-transformed BA measures will also be analyzed.

TTToutput

*Output for Two Times Tmax (TTT) method***Description**

We provides several txt outputs. 1. NCA PK.txt: -> Cmax, Tmax, AUC0t, AUC0inf, AUC0t/AUC0inf, ln(Cmax), ln(AUC0t), ln(AUC0inf), MRT0inf, T1/2, Vd/F, lambda, and CI/F -> PK parameter summary (NCA outputs) 2. plots.pdf: individual linear and semilog plots, spaghetti plots, and mean conc. plots.

3. Statistical summaries.txt

xtick

*x-tick***Description**

Tick for plots.

ytick

*y-tick***Description**

Tick for plots.

Index

*Topic **misc**

aic, [8](#)
AIC_BANOVA, [9](#)
AICdemo, [8](#)
AICoutput, [9](#)
ARS, [9](#)
ARS.BANOVA, [10](#)
ARSdemo, [10](#)
ARSdemo.BANOVA, [10](#)
ARSoutput, [11](#)
BANOVA, [11](#)
BANOVAanalyze, [12](#)
BANOVAcsv, [12](#)
BANOVAdata, [12](#)
BANOVAmenu, [12](#)
BANOVAoutput, [13](#)
BANOVAplot, [13](#)
bye, [13](#)
demoBANOVA, [13](#)
demomenu, [14](#)
demomenu1, [14](#)
demopara, [14](#)
demosize, [14](#)
description_AIC, [14](#)
description_ARS, [15](#)
description_BANOVA, [15](#)
description_drug, [15](#)
description_drugcode, [15](#)
description_import, [16](#)
description_load, [16](#)
description_Multipldrugcode, [16](#)
description_NCA, [16](#)
description_NCAcsv, [16](#)
description_NCAinput, [17](#)
description_ParaMIX, [17](#)
description_ParaNCAcsv, [17](#)
description_ParaNCAinput, [17](#)
description_plot, [18](#)
description_Repdrugcode, [18](#)
description_RepMIX, [18](#)
description_RepNCAcsv, [18](#)
description_RepNCAinput, [19](#)
description_size, [19](#)
description_size_para, [19](#)
description_TOST1_lnAUC0INF, [19](#)
description_TOST1_lnAUC0t, [20](#)
description_TOST1_lnCmax, [20](#)
description_TOST_lnAUC0INF, [21](#)
description_TOST_lnAUC0t, [21](#)
description_TOST_lnCmax, [22](#)
description_TTT, [22](#)
description_TTTAIC, [23](#)
description_TTTARS, [23](#)
description_version, [23](#)
entertitle, [24](#)
entertitle.demo, [24](#)
go, [24](#)
logdata, [24](#)
Multiple1menu, [25](#)
Multipleaic, [25](#)
MultipleAIC_BANOVA, [26](#)
MultipleAICdemo, [25](#)
MultipleAICoutput, [25](#)
MultipleARS, [26](#)
MultipleARS.BANOVA, [26](#)
MultipleARSdemo, [27](#)
MultipleARSoutput, [27](#)
MultipleBANOVA, [27](#)
MultipleBANOVAanalyze, [28](#)
MultipleBANOVAcsv, [28](#)
MultipleBANOVAdata, [28](#)
MultipleBANOVAmenu, [28](#)
MultipleBANOVAoutput, [29](#)
MultipleBANOVAplot, [29](#)
Multipldata, [29](#)
MultipldemoBANOVA, [29](#)
Multipldemomenu, [30](#)
Multipldemomenu1, [30](#)

- Multiplego, 30
- Multiplemenu, 30
- MultipleNCA, 31
- MultipleNCA.BANOVA, 31
- MultipleNCA.BANOVAanalyze, 31
- MultipleNCA.BANOVAcsv, 31
- MultipleNCA.BANOVAdata, 32
- MultipleNCA.BANOVAmenu, 32
- MultipleNCAanalyze, 32
- MultipleNCAcsv, 32
- MultipleNCAdata, 33
- MultipleNCAdemo, 33
- MultipleNCAdemo.BANOVA, 33
- MultipleNCAmenu, 33
- MultipleNCAoutput, 34
- MultipleNCApplot, 34
- MultipleNCAsave, 34
- MultipleNCAseselect, 34
- MultipleNCAseselect.BANOVA, 34
- MultipleNCAselectdemo, 35
- MultipleNCAselectdemo.BANOVA, 35
- MultipleNCAselectsave, 35
- MultipleNCAselectsave.BANOVA, 35
- Multiplentertitle, 35
- Multiplentertitle.demo, 36
- MultipleParaAIC, 36
- MultipleParaAIC.MIX, 36
- MultipleParaAICdemo, 36
- MultipleParaAICoutput, 37
- MultipleParaARS, 37
- MultipleParaARS.MIX, 37
- MultipleParaARSdemo, 38
- MultipleParaARSoutput, 38
- MultipleParadata, 38
- MultipleParademomenu, 38
- MultipleParademomenu1, 39
- MultipleParademoMIX, 39
- MultipleParamenu, 39
- MultipleParaMIX, 39
- MultipleParaMIXanalyze, 40
- MultipleParaMIXcsv, 40
- MultipleParaMIXdata, 40
- MultipleParaMIXmenu, 40
- MultipleParaMIXoutput, 41
- MultipleParaNCA, 41
- MultipleParaNCA.MIX, 41
- MultipleParaNCA.MIXanalyze, 41
- MultipleParaNCA.MIXcsv, 42
- MultipleParaNCA.MIXdata, 42
- MultipleParaNCA.MIXmenu, 42
- MultipleParaNCAanalyze, 42
- MultipleParaNCAcsv, 42
- MultipleParaNCAdata, 43
- MultipleParaNCAdemo, 43
- MultipleParaNCAdemo.MIX, 43
- MultipleParaNCAoutput, 43
- MultipleParaNCApplot, 44
- MultipleParaNCAsave, 44
- MultipleParaNCAseselect, 44
- MultipleParaNCAseselect.MIX, 44
- MultipleParaNCAselectdemo, 44
- MultipleParaNCAselectdemo.MIX, 45
- MultipleParaNCAselectsave, 45
- MultipleParaNCAselectsave.MIX, 45
- MultipleParaTTT, 45
- MultipleParaTTT.MIX, 46
- MultipleParaTTTAIC, 46
- MultipleParaTTTAIC.MIX, 47
- MultipleParaTTTAICdemo, 47
- MultipleParaTTTAICoutput, 48
- MultipleParaTTTARS, 48
- MultipleParaTTTARS.MIX, 49
- MultipleParaTTTARSdemo, 49
- MultipleParaTTTARSoutput, 50
- MultipleParaTTTdemo, 50
- MultipleParaTTToutput, 50
- Multipleplotsingle, 51
- Multipleplotsingle.para, 51
- Multiplestat1menu, 51
- Multiplestatmenu, 51
- MultipleTTT, 52
- MultipleTTT.BANOVA, 52
- MultipleTTTAIC, 53
- MultipleTTTAIC.BANOVA, 53
- MultipleTTTAICdemo, 54
- MultipleTTTAICoutput, 54
- MultipleTTTARS, 55
- MultipleTTTARS.BANOVA, 55
- MultipleTTTARSdemo, 56
- MultipleTTTARSoutput, 56
- MultipleTTTdemo, 57
- MultipleTTToutput, 57
- NCA, 57
- NCA.BANOVA, 58
- NCA.BANOVAanalyze, 58
- NCA.BANOVAcsv, 58

NCA.BANOVAdata, 58
NCA.BANOVAmenu, 59
NCAanalyze, 59
NCAcsv, 59
NCAdata, 59
NCAdemo, 59
NCAdemo.BANOVA, 60
NCAmenu, 60
NCAoutput, 60
NCApplot, 60
NCAsave, 61
NCAsselect, 61
NCAsselect.BANOVA, 61
NCAsselectdemo, 61
NCAsselectdemo.BANOVA, 61
NCAsselectsave, 62
NCAsselectsave.BANOVA, 62
ParaAIC, 62
ParaAIC.MIX, 62
ParaAICdemo, 63
ParaAICoutput, 63
ParaARS, 63
ParaARS.MIX, 64
ParaARSdemo, 64
ParaARSoutput, 64
Paradata, 65
Parademomenu, 65
Parademomenu1, 65
ParademoMIX, 65
Paralleldata, 66
Paramenu, 66
ParaMIX, 66
ParaMIXanalyze, 66
ParaMIXcsv, 67
ParaMIXdata, 67
ParaMIXmenu, 67
ParaMIXoutput, 67
ParaNCA, 67
ParaNCA.MIX, 68
ParaNCA.MIXanalyze, 68
ParaNCA.MIXcsv, 68
ParaNCA.MIXdata, 68
ParaNCA.MIXmenu, 69
ParaNCAanalyze, 69
ParaNCAcsv, 69
ParaNCAdata, 69
ParaNCAdemo, 69
ParaNCAdemo.MIX, 70
ParaNCAoutput, 70
ParaNCApplot, 70
ParaNCAsave, 70
ParaNCAsselect, 71
ParaNCAsselect.MIX, 71
ParaNCAsselectdemo, 71
ParaNCAsselectdemo.MIX, 71
ParaNCAsselectsave, 71
ParaNCAsselectsave.MIX, 72
ParaTTT, 72
ParaTTT.MIX, 72
ParaTTTAIC, 73
ParaTTTAIC.MIX, 73
ParaTTTAICdemo, 74
ParaTTTAICoutput, 74
ParaTTTARS, 75
ParaTTTARS.MIX, 75
ParaTTTARSdemo, 76
ParaTTTARSoutput, 76
ParaTTTdemo, 77
ParaTTToutput, 77
plotsingle, 77
plotsingle.para, 77
plotsingle.Rep, 78
prdcoun, 78
Repaic, 78
RepAIC.MIX, 78
RepAICdemo, 79
RepAICoutput, 79
RepARS, 79
RepARS.MIX, 80
RepARSdemo, 80
RepARSoutput, 80
Repdemomenu, 81
Repdemomenu1, 81
RepdemoMIX, 81
Replicateddata, 81
Repmenu, 82
RepMIX, 82
RepMIXanalyze, 82
RepMIXcsv, 82
RepMIXdata, 83
RepMIXmenu, 83
RepMIXoutput, 83
RepNCA, 83
RepNCA.MIX, 84
RepNCA.MIXanalyze, 84
RepNCA.MIXcsv, 84

RepNCA.MIXdata, 84
RepNCA.MIXmenu, 85
RepNCAanalyze, 85
RepNCAcsv, 85
RepNCAdata, 85
RepNCAdemo, 85
RepNCAdemo.MIX, 86
RepNCAoutput, 86
RepNCAplot, 86
RepNCAsave, 86
RepNCAselct, 87
RepNCAselct.MIX, 87
RepNCAselctdemo, 87
RepNCAselctdemo.MIX, 87
RepNCAselctsave, 87
RepNCAselctsave.MIX, 88
RepTTT, 88
RepTTT.MIX, 88
RepTTTAIC, 89
RepTTTAIC.MIX, 89
RepTTTAICdemo, 90
RepTTTAICoutput, 90
RepTTTARS, 91
RepTTTARS.MIX, 91
RepTTTARSdemo, 92
RepTTTARSoutput, 92
RepTTTdemo, 93
RepTTToutput, 93
Singlego, 93
sizemenu, 93
stat1menu, 94
statmenu, 94
TotalSingledata, 94
TTT, 94
TTT.BANOVA, 95
TTTAIC, 95
TTTAIC.BANOVA, 96
TTTAICdemo, 96
TTTAICoutput, 97
TTTARS, 97
TTTARS.BANOVA, 98
TTTARSdemo, 98
TTTARSoutput, 99
TTTdemo, 99
TTTdemo.BANOVA, 100
TTToutput, 100
xtick, 100
ytick, 100
aic, 8
AIC_BANOVA, 9
AICdemo, 8
AICoutput, 9
ARS, 9
ARS.BANOVA, 10
ARSdemo, 10
ARSdemo.BANOVA, 10
ARSoutput, 11
BANOVA, 11
BANOVAanalyze, 12
BANOVAcsv, 12
BANOVAdata, 12
BANOVAmenu, 12
BANOVAoutput, 13
BANOVAplot, 13
bye, 13
demoBANOVA, 13
demomenu, 14
demomenu1, 14
demopara, 14
demosize, 14
description_AIC, 14
description_ARS, 15
description_BANOVA, 15
description_drug, 15
description_drugcode, 15
description_import, 16
description_load, 16
description_Multipliedrugcode, 16
description_NCA, 16
description_NCAcsv, 16
description_NCAinput, 17
description_ParaMIX, 17
description_ParaNCAcsv, 17
description_ParaNCAinput, 17
description_plot, 18
description_Repdrugcode, 18
description_RepMIX, 18
description_RepNCAcsv, 18
description_RepNCAinput, 19
description_size, 19
description_size_para, 19
description_TOST1_InAUC0INF, 19
description_TOST1_InAUC0t, 20
description_TOST1_InCmax, 20
description_TOST_InAUC0INF, 21

description_TOST_lnAUC0t, 21
description_TOST_lnCmax, 22
description_TTT, 22
description_TTTAIC, 23
description_TTTARS, 23
description_version, 23

entertitle, 24
entertitle.demo, 24

go, 24

logdata, 24

Multiple1menu, 25
Multipleaic, 25
MultipleAIC_BANOVA, 26
MultipleAICdemo, 25
MultipleAICoutput, 25
MultipleARS, 26
MultipleARS.BANOVA, 26
MultipleARSDemo, 27
MultipleARSoutput, 27
MultipleBANOVA, 27
MultipleBANOVAanalyze, 28
MultipleBANOVAcsv, 28
MultipleBANOVAdata, 28
MultipleBANOVAmenu, 28
MultipleBANOVAoutput, 29
MultipleBANOVAplot, 29
Multipledata, 29
MultipledemoBANOVA, 29
Multipledemomenu, 30
Multipledemomenu1, 30
Multiplego, 30
Multiplemenu, 30
MultipleNCA, 31
MultipleNCA.BANOVA, 31
MultipleNCA.BANOVAanalyze, 31
MultipleNCA.BANOVAcsv, 31
MultipleNCA.BANOVAdata, 32
MultipleNCA.BANOVAmenu, 32
MultipleNCAanalyze, 32
MultipleNCAcsv, 32
MultipleNCAdata, 33
MultipleNCAdemo, 33
MultipleNCAdemo.BANOVA, 33
MultipleNCAmenu, 33
MultipleNCAoutput, 34
MultipleNCAsave, 34
MultipleNCAselct, 34
MultipleNCAselct.BANOVA, 34
MultipleNCAselctdemo, 35
MultipleNCAselctdemo.BANOVA, 35
MultipleNCAselctsave, 35
MultipleNCAselctsave.BANOVA, 35
Multiplentertitle, 35
Multiplentertitle.demo, 36
MultipleParaAIC, 36
MultipleParaAIC.MIX, 36
MultipleParaAICdemo, 36
MultipleParaAICoutput, 37
MultipleParaARS, 37
MultipleParaARS.MIX, 37
MultipleParaARSDemo, 38
MultipleParaARSoutput, 38
MultipleParadata, 38
MultipleParademomenu, 38
MultipleParademomenu1, 39
MultipleParademoMIX, 39
MultipleParamenu, 39
MultipleParaMIX, 39
MultipleParaMIXanalyze, 40
MultipleParaMIXcsv, 40
MultipleParaMIXdata, 40
MultipleParaMIXmenu, 40
MultipleParaMIXoutput, 41
MultipleParaNCA, 41
MultipleParaNCA.MIX, 41
MultipleParaNCA.MIXanalyze, 41
MultipleParaNCA.MIXcsv, 42
MultipleParaNCA.MIXdata, 42
MultipleParaNCA.MIXmenu, 42
MultipleParaNCAanalyze, 42
MultipleParaNCAcsv, 42
MultipleParaNCAdata, 43
MultipleParaNCAdemo, 43
MultipleParaNCAdemo.MIX, 43
MultipleParaNCAoutput, 43
MultipleParaNCAplot, 44
MultipleParaNCAsave, 44
MultipleParaNCAselect, 44
MultipleParaNCAselect.MIX, 44
MultipleParaNCAselectdemo, 44
MultipleParaNCAselectdemo.MIX, 45
MultipleParaNCAselectsave, 45

- ParaTTTARS, 75
- ParaTTTARS.MIX, 75
- ParaTTTARSdemo, 76
- ParaTTTARSoutput, 76
- ParaTTTdemo, 77
- ParaTTToutput, 77
- plotsingle, 77
- plotsingle.para, 77
- plotsingle.Rep, 78
- prdcoun, 78

- Repaic, 78
- RepAIC.MIX, 78
- RepAICdemo, 79
- RepAICoutput, 79
- RepARS, 79
- RepARS.MIX, 80
- RepARSdemo, 80
- RepARSoutput, 80
- Repdemomenu, 81
- Repdemomenu1, 81
- RepdemoMIX, 81
- Replicateddata, 81
- Repmenu, 82
- RepMIX, 82
- RepMIXanalyze, 82
- RepMIXcsv, 82
- RepMIXdata, 83
- RepMIXmenu, 83
- RepMIXoutput, 83
- RepNCA, 83
- RepNCA.MIX, 84
- RepNCA.MIXanalyze, 84
- RepNCA.MIXcsv, 84
- RepNCA.MIXdata, 84
- RepNCA.MIXmenu, 85
- RepNCAanalyze, 85
- RepNCAcsv, 85
- RepNCAdata, 85
- RepNCAdemo, 85
- RepNCAdemo.MIX, 86
- RepNCAoutput, 86
- RepNCAplot, 86
- RepNCAsave, 86
- RepNCAselct, 87
- RepNCAselct.MIX, 87
- RepNCAselctdemo, 87
- RepNCAselctdemo.MIX, 87
- RepNCAselctsave, 87

- RepNCAselctsave.MIX, 88
- RepTTT, 88
- RepTTT.MIX, 88
- RepTTTAIC, 89
- RepTTTAIC.MIX, 89
- RepTTTAICdemo, 90
- RepTTTAICoutput, 90
- RepTTTARS, 91
- RepTTTARS.MIX, 91
- RepTTTARSdemo, 92
- RepTTTARSoutput, 92
- RepTTTdemo, 93
- RepTTToutput, 93

- Singlego, 93
- sizemenu, 93
- stat1menu, 94
- statmenu, 94

- TotalSingledata, 94
- TTT, 94
- TTT.BANOVA, 95
- TTTAIC, 95
- TTTAIC.BANOVA, 96
- TTTAICdemo, 96
- TTTAICoutput, 97
- TTTARS, 97
- TTTARS.BANOVA, 98
- TTTARSdemo, 98
- TTTARSoutput, 99
- TTTdemo, 99
- TTTdemo.BANOVA, 100
- TTToutput, 100

- xtick, 100

- ytick, 100